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ABSTRACT  
We used pharmacoepidemiologic methods to overcome barriers innate to studying medication 
use in pregnancy. We applied these methods to two topics of high public health relevance: 1) 
optimal opioid maintenance therapy aimed at decreased neonatal abstinence syndrome (NAS), 
and 2) directing treatment with 17-OHPC for recurrent preterm delivery to women most likely to 
benefit.  
Using a clinical dataset of women exposed to methadone or buprenorphine at Magee-
Womens Hospital, Pittsburgh, PA (2013-2015, n=716), we performed a probabilistic bias 
analysis informed from an internal validation cohort to account for unmeasured confounding by 
maternal addiction severity. The historical increased risk of NAS associated with methadone 
compared with buprenorphine was not entirely attributable to maternal addiction severity 
[conventional adjRR: 1.3 (1.1, 1.5); bias adjRR: 1.2 (1.0, 1.4)]. Next, using an inverse 
probability weighted marginal structural model, we found that the association between treatment 
and NAS was mediated to a considerable degree through preterm birth (~25%). Because infants 
born preterm have lower rates of NAS, and methadone is associated with increased rates of 
preterm delivery, the increased risk of NAS associated with methadone was stronger among term 
births. For every 100 infants born to treated mothers, methadone was associated with 14 excess 
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cases of NAS overall, which increased to 17 excess cases among term births [adjRD: 16.7 (9.3, 
24.0)]. 
To study 17-OHPC, we built models inclusive of significant interactions between 
obstetric history factors to predict the risk of recurrent spontaneous preterm delivery (sptd) in a 
cohort derived from the NICHD MFM Omega-3 trial. This randomized controlled trial found no 
significant effect of omega-3 supplementation on recurrent sptd in addition to administration of 
17-OHPC. Using the treated women in this trial (n=754) and an externally validated predictive 
model, we found that risk of recurrence increased with earliest gestational ages of prior delivery 
only in women with ≥2 previous spontaneous preterm deliveries. These findings support the 
argument that more information, beyond having one previous spontaneous preterm delivery, is 
needed to target therapy to those most likely to benefit. This is of utmost public health 
importance as preterm birth remains the primary contributor to neonatal morbidity and mortality. 
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1.0  INTRODUCTION 
1.1 BACKGROUND 
Medication use in pregnancy is on the rise, despite limited data on safety and efficacy in this 
population [1]. Research in obstetric pharmacology is innately complex, as many barriers exist to 
the study of medication use in pregnant women including the additional risk to the fetus 
associated with treatment, and the changing physiology of pregnancy which affects many aspects 
of the medication’s pharmacology. Pharmacoepidemiology provides a safe and feasible approach 
to the study of medication use and its associated risks and benefits in pregnancy. The goal of this 
project is to apply pharmacoepidemiologic methods to two relevant clinical areas during 
pregnancy where pharmacotherapy is central to treatment: 1) opioid use disorder treatment, 2) 
prevention of recurrent preterm birth. 
A rising issue over the past decade in the U.S., not limited to pregnancy, is the opioid 
epidemic [2, 3]. There are two recommended opioid maintenance therapies in pregnancy, 
methadone and buprenorphine [4]. Current comparative literature of these treatments is plagued 
with biases related to unmeasured confounding from prescribing preferences and inadequate 
accounting for the impact of gestational age. 
Preterm birth, a relatively common obstetric complication, persists as one of the leading 
causes of infant mortality in the U.S. [5, 6]. Women with previous spontaneous preterm births 
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are considered to be at high risk for recurrent preterm birth. The American Congress of 
Obstetricians and Gynecologists (ACOG) recommends prophylactic treatment with progestin 
supplementation in those who are candidates [7]. This treatment practice reduces the risk of 
recurrence by approximately 33% [8]. Previous work identifying women most likely to respond 
to prophylactic treatment has failed to evaluate the interplay between various pregnancy history 
patterns. 
Using pharmacoepidemiologic approaches to study these issues is a feasible approach to 
address issues of high public health priority.  
1.2 SPECIFIC AIMS 
The purpose of this dissertation is to apply pharmacoepidemiologic methods to relevant clinical 
issues encountered by obstetric care providers when prescribing medication in pregnancy. 
Specifically we will address, 1) preferred treatment for opioid use dependence in pregnancy, and 
2) optimizing prophylactic treatment with 17-alpha-hydroxyprogesterone caproate (17-OHPC) 
for recurrent preterm birth with risk assessments based on pregnancy history. We will 
accomplish the following aims using two data sets. To address specific aims one and two, 
described below, we will use pharmacy-billing claims and chart data from all women with 
diagnosed drug-dependent deliveries at Magee-Womens Hospital, Pittsburgh, Pennsylvania, 
from 2013-2015 (n=716). To study our third aim, we will analyze data from ‘The Omega-3 
Trial’, a multi-center, randomized controlled trial conducted at 13 centers by the National 
Institute of Child Health and Human Development (NICHD) Maternal Fetal Medicine Units 
(MFMU) Network from January 2005 to October 2006 (n=754). 
3 
Specific Aim 1. To estimate the association between in utero exposure to methadone 
versus buprenorphine and neonatal abstinence syndrome after accounting for unmeasured 
confounding by severity of maternal addiction.  
Hypothesis: The greater historical risk of neonatal abstinence syndrome with methadone 
compared with buprenorphine-exposed infants will be reduced after accounting for unmeasured 
confounding by severity of maternal addiction. 
Specific Aim 2. To describe and quantify the role of preterm birth in the association 
between opioid maintenance therapy and neonatal abstinence syndrome. 
Hypothesis: The increased risk of neonatal abstinence syndrome associated with 
methadone exposure compared with buprenorphine will be stronger in infants delivered after 36 
completed weeks of gestation because of preterm birth’s role as a mediator. 
Specific Aim 3. To build a model predictive of recurrent preterm birth that elucidates the 
interrelationship between pregnancy histories on the risk of recurrent spontaneous preterm birth 
among women treated prophylactically with weekly 17-alpha-hydroxyprogesterone caproate 
injections. 
Hypothesis: Predicted risk of recurrent preterm delivery will be most influenced by the 
gestational age of the earliest previous spontaneous preterm deliveries, but this effect will be 
modified by the number of previous spontaneous preterm births in women treated with 17-alpha-
hydroxyprogesterone caproate intramuscular injections. 
Overall Impact: These results may alter treatment preferences for medications used for 
women with an opioid use disorder in pregnancy. Additionally, for use of 17-OHPC, these 
results will stratify risk and facilitate a patient specific risk profile which will enable treatment to 
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be better targeted to those most likely to benefit. Taken together, this work will demonstrate the 
utility of applying epidemiologic methods to the study of medication use in pregnancy. 
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2.0  LITERATURE REVIEW 
2.1 INTRODUCTION 
2.1.1 Pharmacotherapy in pregnancy 
Medication use in pregnancy is on the rise. More than 90% of pregnant women in the U.S. 
used at least one over the counter or prescription medication during pregnancy in 2006-2008; 
with an average of 4 medications [1]. The number of women entering pregnancy already 
receiving treatment for chronic conditions, such as hypertension or opioid use disorder, and 
women receiving medication therapy for gestation-related conditions such as preeclampsia, 
gestational diabetes or preterm labor, have both recently increased.  
Despite these increases in utilization, very little is known about medication safety and 
efficacy in pregnancy. There are several factors contributing to the paucity of data in pregnancy. 
A major barrier is the enormous liability concerns that discourage pharmaceutical companies and 
academics from studying pregnant women. The additional risk posed to both mother and fetus is 
often enough to prohibit randomized clinical trials and to discourage participant involvement [9]. 
An additional disincentive to the pharmaceutical industry is that a pregnant woman’s care 
provider often will continue to provide medications if the clinical circumstances demand that the 
medication be used, despite a lack of precise pharmacological information.  
6 
Further complicating research in this population is the need for long-term follow-up for 
childhood outcomes. To fully quantify the risk of outcomes such as attention deficit hyperactive 
disorder, follow-up must be adequate. In addition to long lengths of follow-up, large sample 
sizes are required to document associations with rare birth defects. For example, the most 
common birth defect diagnosed in the U.S., congenital heart defects, occur at a rate of about 1% 
with an estimated 40,000 affected births each year in the U.S. [10, 11]. In order to demonstrate 
an increased risk resulting from medication exposure, investigators may need thousands of 
pregnant women with documented exposure to the medication of interest.  
As a way to overcome the aforementioned challenges, large exposure registries in 
pregnancy that facilitate pharmacoepidemiologic research should be supported. This is a 
practice now being implemented through post marketing surveillance and the new Food and 
Drug Administration (FDA) Pregnancy and Lactation Labeling Rule. Utilizing large, extant 
databases minimizes a number of the previously described limitations. Benefitting from the fact 
that pregnant women often continue medication use in pregnancy, and analyzing this data 
retrospectively is a safe approach to address the risks and benefits of treatment in large 
populations. Epidemiologic and statistical methods are then needed to overcome the new biases 
inherent in observational data. Only when these studies, along with pharmacokinetic and 
pharmacodynamic studies, are performed more regularly, will we have enough data to define the 
associated efficacy and risks of medication use in pregnancy. Such large data repositories were 
used in this project to study medication use and optimization in pregnancy.  
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2.2 OPIOID USE DISORDER IN PREGNANCY 
The use of prescription opioids and heroin has dramatically increased over the past decade 
in the U.S. [2, 12]— a trend that is consistent not only in women of childbearing age [13] 
but also extends to pregnancy [3, 14]. From 1998 to 2011 the reported prevalence of opioid 
abuse or dependence in pregnancy increased by 127% [14]. Opioid use disorder includes abuse 
of or dependence on prescription opioids and/or heroin. The DSM-IV and DSM-V criteria for 
opioid use disorder were used to create the International Classification of Disease (ICD) codes 
indicating opioid use disorder.  
2.2.1 Medication treatment options 
Current guidelines suggest replacement therapy, termed opioid maintenance therapy, over 
detoxification in pregnancy due risk of fetal demise and maternal relapse [4, 15]. Maintaining 
opioid exposure throughout pregnancy with such treatments decreases risk of withdrawal and 
relapse while also reducing risky behaviors associated with obtaining opioids illegally. The 
American Congress of Obstetricians and Gynecologists (ACOG) guidelines support the use of 
methadone or buprenorphine.  
Methadone is a Schedule II, full opioid agonist and has been the mainstay of care 
for opioid replacement since the 1970s. Conversion to methadone treatment can be done at a 
licensed outpatient program, or through inpatient services contingent on transfer to a methadone 
clinic post-discharge [4]. Initial doses are tailored to withdrawal symptoms, with subsequent 
dose changes throughout pregnancy accommodating altered physiologic and pharmacokinetic 
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states that occur in pregnancy. In the U.S., methadone treatment must be obtained through a 
daily visit to a licensed methadone provider [16].  
In 2002, buprenorphine, a partial opioid agonist, was approved for treatment of 
opioid use dependence. Benefits gained with this drug’s arrival on the market are less drug-drug 
interactions, less abuse and overdose potential, and availability at outpatient clinics [17]. 
Buprenorphine is available as its pure form (Subutex®), or in combination with an opioid 
antagonist, naloxone, intended to decrease diversion and abuse (Suboxone®). Buprenorphine 
alone (Subutex®) is generally preferred in pregnancy to avoid exposure to naloxone which has 
unknown fetal safety data. Buprenorphine is classified as a schedule III narcotic, and can 
therefore be prescribed with a prescription in an office setting by a specifically licensed 
prescriber for up to 30 days [18]. Use of buprenorphine in pregnancy has been on the rise 
since its FDA approval [17] likely due to its potentially superior perinatal outcomes [17, 
19]. 
2.2.2 Neonatal abstinence syndrome 
Neonatal abstinence syndrome (NAS) is the term used for postnatal opioid withdrawal that 
can occur among infants exposed in utero to opioids, including maintenance therapies [20]. 
Not surprisingly, increasing trends in NAS have paralleled the opioid epidemic in the U.S. with a 
nearly three-fold increase in prevalence from 2000 to 2009 [21]. NAS is expected to occur in up 
to 94% of infants exposed to opioids in utero [22]. 
The exact pathophysiology of NAS remains unknown [23]. NAS may present as a variety 
of symptoms originating from the autonomic and central nervous systems. Such symptoms 
include, but are not limited to, irritability, tremors, seizures, diarrhea, sleep disturbances, 
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respiratory distress, feeding difficulties, failure to thrive, and rarely neonatal demise [20, 22, 23]. 
These symptoms are monitored using the Finnegan Scale for NAS diagnosis.   
The Finnegan Scale is the most commonly used tool to evaluate neonates for NAS [20, 
24]. Though it has been argued to be too subjective, no objective scoring instrument exists at this 
time. The American Academy of Pediatrics recommends that all infants with known in utero 
exposure to opioids be monitored in the hospital for 5 to 7 days postpartum. This extended 
period allows health professionals to administer the Finnegan Scale over many days, as timing of  
NAS presentation varies by opioid type [20].  
The most commonly used pharmacologic treatment in infants requiring medication 
in the U.S. is morphine or methadone administration, with dosing tailored to symptoms of 
withdrawal [20]. Non-pharmacologic care for NAS is largely undefined [20], and pharmacologic 
protocols vary by institution [25]. 
In addition to the discomfort and short-term risks resulting from NAS, it is also 
associated with long-term adverse effects. There have been documented associations with 
decreased visual acuity [26], ear infections and behavioral and cognitive impairments [27]. 
Finally, NAS is a large burden on our healthcare system. In 2009 alone, hospital charges 
associated with NAS totaled an estimated $720 million [21].  
2.2.3 State of the current evidence  
The landmark randomized controlled trial (RCT) comparing opioid maintenance therapies 
in pregnancy is the MOTHER (Maternal Opioid Treatment: Human Experimental 
Research) Trial. The findings of this RCT demonstrated superior perinatal outcomes with 
use of buprenorphine compared with methadone including less severe NAS. The MOTHER 
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Trial was a double-blind, flexible-dosing, RCT, that randomized opioid dependent pregnant 
women to treatment with buprenorphine or methadone at 8 international cites from 2005 to 2008. 
In the final analysis of 73 pregnancies exposed to methadone and 58 to buprenorphine, authors 
found significantly lower NAS treatment doses (mean dose, 1.1 mg vs. 10.4 mg) with shorter 
duration (4.1 days vs. 9.9 days), and shorter hospital stays (10.0 days vs. 17.5 days) in the 
buprenorphine-treated group. Despite these differences, there was no statistically significant 
difference in the incidence of NAS nor the peak NAS score (47 vs. 57%, buprenorphine vs. 
methadone, respectively). 
Comparative studies of methadone versus buprenorphine in pregnancy have been 
recently summarized in two large meta-analyses, both inclusive of the seminal MOTHER 
Trial [28]. The findings of these meta-analyses summarizing the past fifteen years of 
publications are in general agreement that buprenorphine is associated with superior 
perinatal outcomes compared with methadone.  
In a meta-analysis conducted in 2014 by Brogly et al., authors assessed the risk of a 
variety of outcomes associated with each treatment. Authors combined and analyzed 12 studies 
comprised of 855 in utero exposures to methadone and 515 in utero exposures to buprenorphine 
from 1996 to 2012. They found that infants exposed to buprenorphine compared with methadone 
had longer gestations, higher birth weights, lengths and head circumferences at birth. These 
authors also found that the risk of NAS was lower in buprenorphine treated pregnancies [Risk 
Ratio (RR) = 0.90, 95% CI: 0.81, 0.98], with lower treatment doses (−3.60 mg, 95% CI: −7.26, 
0.07), shorter durations of treatment (−8.46 days, 95% CI: −14.48, −2.44) and shorter hospital 
stays (−7.23 days, 95% CI: −10.64, −3.83). Results also demonstrated that mothers receiving 
buprenorphine treatment were less likely to use illicit opioids near time of delivery [19].  
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A meta-analysis conducted by Zedler et al. two years later, comprised of three RCTs 
(n=233) and 15 observational studies (n=1923),  supported these findings showing buprenorphine 
to be associated with a lower risk of preterm birth [RCT: RR = 0.40, 95% CI: 0.18, 0.91; 
observational (OBS): RR = 0.67, 95% CI: 0.50, 0.90], increased birth weight [RCT: weighted 
mean difference (WMD) = 277 g, 95% CI: 104, 450; OBS WMD = 265 g, 95% CI: 196, 335] 
and larger head circumference (RCT WMD = 0.90 cm, 95% CI: 0.14, 1.66; OBS WMD = 0.68 
cm, 95% CI: 0.41, 0.94) compared with methadone. This review did not address risk of NAS 
[17]. Zedler found no significant difference between fetal death nor congenital malformations, 
and Brogly et al. did not include this in their outcome assessments.  
2.2.4 Major limitations in the literature 
2.2.4.1 Unmeasured confounding 
A significant bias in the comparison of methadone and buprenorphine is inherent in this 
research due primarily to the differing delivery systems in the U.S. Because the delivery 
system for buprenorphine allows for more diversion, often women who are considered more 
‘trustworthy’ by the provider and less likely to relapse and divert the drug are prescribed 
buprenorphine. Conversely, women who are considered less reliable, likely with more severe 
addiction, are frequently thought to benefit from the daily observed therapy that methadone 
treatment mandates. Moreover, women with severe addiction will often choose to be treated with 
methadone as they feel it is a more powerful opioid agonist. This creates the potential for 
confounding by severity of opioid addiction — a factor that contributes both to opioid 
maintenance therapy selection and potentially to risk of NAS. In observational studies, it is 
difficult to collect data on severity of addiction and prescribing preferences partially due to the 
12 
strong stigma associated with opioid use disorder in pregnancy. Therefore, retrospective datasets 
used to study this topic are typically limited by an absence of detailed information on both 
addiction and treatment trajectories. Even in prospective studies, this information is generally 
lacking as this population is notoriously difficult to follow. The resulting, often unmeasurable, 
differences in treated patient populations makes it difficult to compare the direct effects of 
these medications using standard statistical methods. 
Even the landmark MOTHER RCT [28] was plagued with this intrinsic bias. In this RCT 
that found buprenorphine to be associated with less severe NAS compared with methadone, 33% 
of women randomized to buprenorphine discontinued treatment, with 71% of them reporting 
“dissatisfaction” with treatment. This is in stark contrast to only 18% of methadone patients 
discontinuing treatment, of which only 13% reported “dissatisfaction” with treatment. These 
women were considered “lost to follow-up” and their treatment trajectories were not followed; 
however, in clinical practice patients can be converted from buprenorphine to methadone but not 
vice versa due to buprenorphine’s antagonist effect which precipitates withdrawal. The 
differences in attrition by treatment group introduce the possibility that women with more severe 
addiction remained only in the methadone-treated group. If this occurred, benefits seen with 
buprenorphine treatment may in fact be attributable to the severity of opioid dependence in the 
methadone-treated group. Investigators had very few markers of severity of addiction and were 
therefore unable to assess if severity differed by treatment in the final analytic population, which 
was limited to women compliant with randomized medication. Furthermore, despite 
randomization, women allocated to methadone treatment had longer cumulative lifetime drug 
use. These factors result in similar biases seen in observational studies. Authors of the MOTHER 
Trial attempted to address the bias by repeating analyses in a sub-cohort limited to women 
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receiving an arbitrarily determined ‘high-dose’ of methadone (≥100mg), as a marker of severe 
addiction, compared with buprenorphine. They found no difference in results, but were 
underpowered to detect a difference. 
This bias in prescribing preferences, whether referred to as confounding by severity 
or indication, is acknowledged widely in the literature today, but is rarely addressed [29-
31]. The majority of existing cohort studies conducted unadjusted analyses [32-35] or adjusted 
for the limited variables available in their data sets that may be related to severity of addiction 
such as education, race, indication for opioid maintenance, maternal age, and/or smoking status 
but few to no direct markers of severity (e.g. documented relapse) [36, 37]. Unfortunately a few 
extended to control for variables that may be on the causal pathway of the association between 
opioid maintenance therapy and NAS, such as adequacy of prenatal care, gestational age at 
initiation of treatment, and heroin use in pregnancy [38, 39]. 
To our knowledge, the only study beyond the MOTHER Trial that attempted to address 
unmeasured confounding, despite it being commonly mentioned as a limitation of publications, 
was in the meta-analysis conducted by Brogly et al. The authors conducted a sensitivity analysis 
to address the role of unmeasured confounding, applying this specifically to the association 
between opioid maintenance therapy and NAS. The results of this analysis were limited as 
authors chose subjective parameters derived from extant literature alone that were admittedly 
based on strong assumptions. The association of treatment with NAS became null in the results 
of the sensitivity analysis. Similar bias analyses have been replicated with slight changes in the 
bias inputs that resulted in minimal changes from the original results, contrary to Brogly’s 
findings [31]. Up to this point, the only study using epidemiologic methods to address this 
well-documented bias, was informed entirely from extant literature. 
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Our study is innovative as it is the first to utilize empirical data to inform the 
parameters of the bias analysis. This approach eliminates the subjectivity of applying data 
from the literature, and allows us to use tighter ranges of potential values based upon surrogate 
markers of severity of addiction in our internal validation cohort. 
2.2.4.2 Role of gestational age 
The current literature comparing buprenorphine with methadone use in pregnancy 
generally ignores the role of gestational age, or inappropriately attempts to account for it 
by adjusting for gestational age [39, 40]. Gestational age is inherently a complex issue in 
perinatal research, one that is frequently ignored despite the fact that it can have significant 
impact on findings and conclusions [41, 42]. Gestational age plays an important role in the 
association between opioid maintenance therapy and NAS.  
Methadone is associated with preterm birth, both in comparison with no treatment or 
with buprenorphine [17, 37, 39, 43, 44]. Preterm birth is associated with a lower frequency 
and less severe NAS after exposure to methadone [45-47]. Therefore, gestational age may in 
fact lie on the causal pathway of this association and therefore should be assessed as a mediator. 
When gestational age is adjusted for, this assumes that gestational age is associated with both 
treatment and NAS. However, due to the temporality of these relationships, gestational age 
cannot contribute to treatment choice and therefore does not meet the criteria of a confounder. 
When gestational age is included in the model as a confounder, the association is generally 
biased away from the null, conferring an even higher benefit associated with buprenorphine use 
compared with methadone. Alternatively, not addressing gestational age through adjustment nor 
methods like a survival analysis, demonstrates the association that is a result of both treatment 
and gestational age together.  
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No study to date has attempted to isolate the role of gestational age in the 
association between methadone and NAS compared with buprenorphine. Because preterm 
birth may mediate the association, the true association between methadone and NAS compared 
with buprenorphine may in fact be stronger than is documented when the association is studied 
among term births alone. By evaluating the role of gestational age as mediator, our study will be 
the first to quantify the risk of NAS associated with opioid maintenance therapy 
independent of prematurity.  
2.3 SPONTANEOUS PRETERM BIRTH IN THE U.S. 
Preterm birth remains a leading cause of neonatal and infant mortality, contributing to an 
estimated 75% of all perinatal deaths [5, 6, 48, 49]. Preterm birth is defined as delivery prior to 
37 weeks’ gestation. Nearly 1 out of every 10 live born infants is delivered preterm in the United 
States [50], costing an estimated $26 billion in 2006 [51]. Preterm birth carries with it severe 
short and long term sequelae including respiratory difficulties, intracranial hemorrhage, 
infection, necrotizing enterocolitis, and developmental disabilities to name a few [52]. Preterm 
birth can be defined generally as medically necessary (30-35%) for maternal or fetal indications, 
or as spontaneous (65-75%) [49]. This work will focus solely on spontaneous preterm births. 
Generally, spontaneous preterm birth is caused by preterm labor or preterm premature rupture of 
membranes (pPROM). Preterm labor, the more common cause of spontaneous preterm birth, is 
defined as “regular contractions of the uterus resulting in changes in the cervix that start before 
37 weeks of pregnancy” [48]. The exact mechanism triggering preterm labor is unknown. 
Similarly, the cause of the majority of pPROM cases are also unknown. PPROM is defined as 
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spontaneous rupture of the membranes prior to 37 weeks’ gestation. Preterm labor and pPROM 
share the majority of their known risk factors, with pPROM occurring more commonly in 
women with undiagnosed intrauterine infections [49]. 
2.3.1 Obstetric history as a risk factor for preterm birth 
Predicting preterm birth is difficult as the pathophysiology is not well-defined and is likely 
multi-factorial. Despite this, it is accepted that previous spontaneous preterm birth is one of the 
strongest predictors of recurrent preterm birth [7, 53-56]. Along with obstetric history, risk 
factors range from genetic and biologic differences to behaviors and factors unique to the current 
pregnancy. Each of these broad categories has been studied with conflicting results. This project 
will focus on obstetric history and its role in predicting recurrent spontaneous preterm birth.  
The characteristics of obstetric history that are most commonly studied and thought 
to contribute to risk of recurrent spontaneous preterm birth are: the gestational age at 
which previous preterm birth(s) occur(s), the number of previous preterm and term births, 
the outcome of the most recent pregnancy, and the cause(s) of previous preterm birth(s).  
Studying which of these obstetric history factors is the most predictive of recurrent 
preterm birth and their influence on each other is critical as this could optimize treatment in those 
women most likely to respond. This approach may also elucidate potential mechanisms of 
preterm birth that are consistent across pregnancies. 
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2.3.2 17-alpha-hydroxyprogesterone caproate 
17-alpha-hydroxyprogesterone caproate (17-OHPC) is currently the only FDA-approved 
formulation of injectable progestin with the indication of prevention of recurrent 
spontaneous preterm birth in singleton pregnancies with a history of a singleton 
spontaneous preterm birth. For decades, there was no effective treatment for the prevention of 
preterm birth. Today, only one medication therapy-beyond physical interventions such as 
cerclage and cervical pessaries-has been proven to be efficacious in preventing recurrent preterm 
birth in high-risk women: progestin.  
Progesterone, a hormone occurring naturally and sustaining early pregnancy, is known to 
suppress uterine contractions and promote uterine quiescence, though the exact mechanism is 
unknown [57]. A commonly accepted biologic mechanism of preterm birth stems from evidence 
that anti-progestins increase myometrial contractions [58]. By extension, progesterone 
withdrawal may contribute to labor. These hypotheses fueled research into 17-OHPC as a 
prophylactic treatment for preterm birth. Progestins have been tested for preterm birth prevention 
as both an intramuscular weekly injection, supplied as 17-OHPC, and vaginally in micronized 
form. In 2003, a seminal trial conducted by Meis et al., described in detail below (section 
2.3.3.1), demonstrated a decreased risk of recurrent preterm birth by approximately 34% in 
women with a prior spontaneous preterm birth who were treated prophylactically with 17-OHPC 
intramuscular injections [8]. Largely as a result of these findings and expert opinions, adoption 
of 17-OHPC use in this high risk population has been widely accepted and implemented.  
In fact, current ACOG guidelines recommend that women with singleton gestations 
and a history of at least one prior spontaneous preterm singleton birth be treated with 17-
OHPC injections. This treatment is administered as a weekly 250 mg intramuscular injection 
18 
initiated at 16 to 24 weeks gestation and continued until 36 weeks of completed gestation or 
delivery, whichever occurs first. In keeping with clinical practice, this project will focus on the 
use of 17-OHPC injections as prophylactic treatment for spontaneous preterm birth in women 
with a history of spontaneous preterm birth of a singleton. 
2.3.3 Review of the current evidence of 17-alpha-hydroxyprogesterone caproate in the 
prevention of recurrent preterm birth 
It is a public health priority to better identify women at high risk for recurrent preterm 
birth, and furthermore those most likely to benefit from prophylactic treatment with 17-
OHPC as it is the only currently available therapeutic option. Consistent with the aims of 
this project, this review will focus on studies identifying women most likely to respond to 17-
OHPC injection therapy based on obstetric history. Current research aimed at decreasing preterm 
birth has 3 general concentrations: 1) identification of women at the highest risk for preterm 
birth, 2) identifying women most likely to benefit from treatment, and 3) developing further 
therapeutic options to prevent preterm birth. Our project primarily addresses the first two arms of 
this research. Each study included in the review defined preterm birth as delivery prior to 36 
weeks of completed gestation unless otherwise noted.  
2.3.3.1 Studies assessing the effect of gestational age of earliest spontaneous preterm birth, 
number of previous spontaneous preterm births, and gestational age of penultimate 
pregnancy  
The landmark trial assessing the utility of 17-OHPC, mentioned previously, was conducted by 
Meis et al. in 2003 [8]. This was a double-blind, placebo-controlled RCT conducted at 19 clinical 
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centers from 1998-1999. Recruitment was limited to women with at least one previous 
spontaneous preterm delivery between 20 and 366 weeks of gestation. Participants were 
randomized in a 2:1 manner to treatment with weekly 250mg injections of 17-OHPC (n=310) or 
inert oil placebo (n=153) beginning at 16 to 206 weeks gestation and continuing through 366 
weeks gestation or until delivery. These authors found that 17-OHPC significantly decreased 
the risk of recurrent preterm birth prior to 37 weeks (RR 0.66, 95% CI: 0.54, 0.81) and at 
less than 32 weeks (RR 0.58, 95% CI: 0.37, 0.91).  
Two secondary analyses of this cohort were conducted by Meis et al. and Spong et al. in 
2005 [53, 59]. The objective of the first, conducted by Meis et al., was to assess how maternal 
age, race, parity, prepregnancy body mass index (BMI), education, smoking status, alcohol use, 
number of previous preterm deliveries, number of previous abortions or miscarriages, number of 
total previous deliveries, interval since preterm delivery, history of a previous term delivery, and 
gestational age of penultimate pregnancy (term vs. preterm) influenced the risk of recurrent 
preterm birth and further how these factors influenced the effectiveness of treatment with 17-
OHPC [53]. Authors conducted all univariate logistic regressions separately by exposure to 17-
OHPC, assessing which variables were associated with recurrent preterm birth in each group. 
Their final models showed that women treated with placebo had increased risk of recurrent 
preterm birth if they experienced more than 1 previous preterm delivery, the penultimate delivery 
was preterm, and if the patient was obese prior to pregnancy. In the women treated with 17-
OHPC, the increased risk attributed to a history of more than one previous preterm birth was 
eliminated and only the increased risk associated with a preterm penultimate pregnancy 
remained. These authors concluded that treatment with 17-OHPC principally reduces the risk 
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associated with more than one previous preterm birth, in addition to an overall benefit of 
decreased preterm birth risk in women with a history of previous spontaneous preterm birth.  
Again utilizing the data from the seminal trial, Spong et al. evaluated if the effectiveness 
of 17-OHPC varied by gestational age of the earliest previous spontaneous preterm delivery, 
classified as 20-27.9, 28-33.9, and 34-36.9 weeks [59]. Analysis consisted of statistical 
comparisons between groups of earliest gestational ages, logistic regressions within each 
subgroup adjusted for African American race, Hispanic ethnicity, gestational age at 
randomization, and more than one previous spontaneous birth, and a Cox Proportional Hazards 
survival analysis with censoring at 37 weeks. Findings from this secondary analysis supported an 
overall decrease in risk of recurrent spontaneous birth with 17-OHPC use, and further found the 
greatest benefit of treatment in women with earliest gestational ages of <34 weeks.  
Taken together, these secondary analyses demonstrated that in addition to an overall 
benefit of decreased preterm birth risk in women with a history of previous spontaneous preterm 
birth, that treatment with 17-OHPC principally reduced the risk associated with more than 
one previous preterm birth and was most effective in women with a prior spontaneous 
preterm birth before 34 weeks’ gestation. 
In an additional retrospective cohort, investigators analyzed records from women with a 
singleton gestation and at least one prior spontaneous preterm birth with 17-OHPC delivered 
according to provider discretion as routine care [60]. These authors shared the same primary aim 
as Spong et al, to determine how the earliest gestational age of a previous spontaneous preterm 
birth (classified as 20-27.9, 28-33.9, and 34-36.9 weeks) impacted the effectiveness of 17-
OHPC. A total of 2978 women received treatment with 17-OHPC and 1260 did not, despite 
history of spontaneous preterm birth. Contrary to Spong et al. [59], findings demonstrated that 
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17-OHPC showed similar benefit and decreased rates of spontaneous preterm birth regardless of 
gestational age at earliest preterm birth. Incidence of recurrent preterm birth in the 17-OHPC 
treated compared with the untreated were: 32.2% vs 40.7% in 20-27.9 weeks, 34.1% vs 45.5% in 
28-33.9 weeks, and 29.3% vs 38.8% in 34-36.9 weeks. These results are likely biased as, without 
randomization, women who received treatment with 17-OHPC were different than those who 
opted for no treatment. Specifically, the group with the earliest documented gestational ages at 
20-27.9 weeks in previous pregnancies were more likely to receive treatment with 17-OHPC 
compared with those with an earliest age of 34.9-36 weeks. This confounding relationship is 
unaccounted for; however, other potential confounders such as Black race, more than 1 previous 
preterm delivery, and smoking status were adjusted for.  
Incorporating appropriate weights for each study’s biases and limitations, the 
results of these studies support the overall benefit of 17-OHPC implementation with an 
additional benefit gained in women with earlier previous gestational ages.  
2.3.3.2 Studies comparing the risk of recurrent preterm birth by indication of previous 
preterm birth 
The difference in risk of recurrent spontaneous preterm birth by indication of previous 
spontaneous preterm birth, preterm labor versus preterm premature rupture of membranes 
(pPROM), is another obstetric history characteristic of interest. This factor was not addressed in 
the seminal RCT, which included women with either type of spontaneous preterm birth history. 
Gonzalez-Quintero approached this question using a dataset of 2,123 women with singleton 
gestations and a history of one prior spontaneous preterm birth being administered weekly 17-
OHPC [61]. Findings from unadjusted logistic regressions demonstrated that women with 
preterm labor had higher rates of recurrent spontaneous preterm birth compared with those 
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delivered for pPROM at both 37 (29.7 vs. 2,2.9%) and 32 weeks (5.9 vs. 3.3%). However, in this 
study women with a history of preterm labor also had a higher incidence of previous preterm 
births at 20 to 27.9 weeks compared with 28 to 33.9 weeks in the pPROM group.  Therefore, the 
conclusions of these investigators that the previous clinical preterm birth presentation influences 
the risk of recurrent preterm delivery may in fact be reflective of the impact of gestational age. 
The authors went further and concluded that beyond the type of previous spontaneous preterm 
birth, the gestational age of the prior preterm birth was also associated with recurrence- though 
the effect of previous gestational age varied by previous clinical presentation. In women with a 
history of preterm labor there was no association between previous gestational age and recurrent 
preterm birth. Conversely, in women with a history of pPROM, the rate of recurrence was 
highest in those with a previous delivery at a gestational age of 28-33.9 compared with both 
deliveries <28 weeks and ≥34 weeks. This association is likely an artifact of their unadjusted 
approach and lack of placebo-controlled group for comparison. Though rates of recurrence are 
typically higher in the earlier previous age groups, women in these earlier groups may benefit 
more from treatment [59].  
Similar to Gonzalez-Quintero et al., Coleman et al. used a database inclusive of 1,183 
singleton pregnancies with a history of a preterm birth in the previous pregnancy and current 
treatment with 17-OHPC. They assessed the risk of recurrent preterm birth by the clinical 
presentation of the penultimate preterm birth—i.e. preterm labor versus pPROM [56]. Using 
unadjusted logistic regression models they found three obstetric history variables that 
significantly increased the risk of recurrent preterm birth despite treatment: more than one 
previous preterm birth (OR 1.80, 95% CI: 1.33, 2.44), a penultimate birth at 28 to 33.9 weeks’ 
gestation compared with 34–36.9 weeks’ gestation (OR 1.61, 95% CI: 1.22, 2.13), and 
23 
penultimate delivery presenting as preterm labor compared with pPROM (OR 1.66, 95% CI: 
1.16, 2.37). These findings are generally consistent with Gonzalez-Quintero’s work above, 
demonstrating an increased risk of recurrent preterm birth despite treatment with 17-
OHPC in women with a history of preterm labor compared with pPROM and in those with 
earlier gestational age of most recent preterm birth. It is important to note that the results 
from each of these studies are derived from unadjusted analyses.  
2.3.3.3 Studies evaluating “response” versus “no response” to 17-alpha-
hydroxyprogesterone caproate 
Recently a group of authors redefined treatment ‘response’ to 17-OHPC by classifying the 
difference in gestational age from the 17-OHPC treated pregnancy and the woman’s earliest 
spontaneous preterm birth. Prolongation of gestational age by three or more weeks from a 
subject’s earliest spontaneous preterm birth was considered ‘response’. Authors were attempting 
to better classify utility of 17-OHPC, but in doing so may have lost clinical relevance. Under this 
definition infants born at 24 weeks would be classified as ‘responders’ if the earliest previous 
preterm birth occurred at 20 weeks. In practice these infants remain at risk for the negative 
effects associated with preterm birth and therefore may not have benefitted significantly from 
treatment.  
This new outcome was applied using data from Eunice Kennedy Shriver NICHD 
Genomic and Proteomic Network for Preterm Birth Research. Manuck et al. performed a 
retrospective study evaluating the effect of pregnancy history, maternal demographics and 
antenatal factors on the gestational age in pregnancy treated with 17-OHPC [62]. ‘Responders’ 
(n=118) were compared with ‘non-responders’ (n=37) for statistical differences in 
characteristics. In this study authors used a stepwise backward elimination process to define the 
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logistic regression model, including all variables with a p-value <0.20 in the final model. Only 
two obstetric history variables were tested, 1) gestational age of the earliest previous spontaneous 
preterm birth, and 2) a history of abruption in a previous pregnancy. Results showed that the only 
pregnancy history factor that predicted treatment response was the gestational age of the earliest 
previous spontaneous preterm birth (OR 0.68, 95% CI: 0.56, 0.82). Results were consistent when 
the cohort was limited to women with a penultimate preterm birth, as this was associated with 
nonresponse to treatment. Additional factors, beyond obstetric histories, that remained predictive 
in the final model included vaginal bleeding or abruption in the current pregnancy and first 
degree family history of spontaneous preterm birth- consistent with the authors’ previous 
findings [63]. 
An additional secondary analysis, conducted by the same group, again used the “response 
vs. nonresponse” outcome. This study utilized a cohort of women all treated with 17-OHPC from 
the NICHD MFMU RCT titled “Omega-3 Trial”, the same cohort used in this project [63]. This 
RCT compared the effect of omega-3 supplementation with placebo in a cohort of 852 women 
with a history of spontaneous preterm birth and treated with weekly 17-OHPC injections. 
Omega-3 supplementation had no significant effect on outcomes or effect of 17-OHPC. The 
objective of this secondary analysis was to create a clinical risk scoring system based on the 
novel definition of ‘response’ to treatment in place of the standard preterm birth definition. The 
final analytic sample consisted of 595 ‘responders’ (of which 27% still had a preterm birth) and 
159 ‘nonresponders’, all treated with 17-OHPC. Using multivariate logistic regression they 
identified risk factors for ‘nonresponse’ which included two obstetric history variables: each 
additional week of gestation of earliest previous preterm birth (OR 1.23, 95% CI: 1.17, 1.30) and 
a penultimate preterm birth (OR 2.10, 95% CI: 1.03, 4.25). No other obstetric history variables 
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were tested in the multivariable analysis. Variables independently significant in predicting 
nonresponse beyond obstetric history included placental abruption or significant vaginal bleeding 
in the current pregnancy, diagnosis of gonorrhea and/or chlamydia, and having a male fetus. 
When this prediction model was validated in a separate sample it had a sensitivity and specificity 
of only 65% and 67%, respectively, but findings were consistent with their previous study.  
Applying the new outcome definition of ‘response’ findings continued to support the 
association between gestational age of earliest preterm birth and outcome of penultimate 
pregnancy with recurrent preterm birth. Similar to the two secondary analyses of the Meis trial 
[8], both studies concluded that women with earlier previous gestational ages, and 
penultimate term births are more likely to ‘respond’ to treatment with 17-OHPC, and 
therefore are less likely to have a preterm birth.  
Notwithstanding significant biases, the extant literature taken together is consistent 
and supports an effect of obstetric history on the effectiveness of 17-OHPC. 
2.3.3.4 Major gaps in the literature 
Notwithstanding the vast amount of literature assessing the role of obstetric history in 
recurrent preterm birth despite treatment with 17-OHPC, no study to date has assessed the 
interplay between these characteristics. It is reasonable to expect that the risk associated with 
one factor, for example number of previous spontaneous preterm births, would be modified by 
another such as the age at which the earliest occurred. Assessing each of these individually rather 
than in concert is a gap in the literature that we will fill by completing this aim. We will address 
this critical gap by evaluating interactions between each available obstetric history 
variable. 
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Furthermore, the majority of the extant literature did not adjust for crucial 
confounders when assessing various risk factors. In simple epidemiologic terms, all factors 
known to be associated with both the exposure (17-OHPC or obstetric history variable) and the 
outcome (recurrent preterm birth) that are not on the causal pathway should be considered 
potential confounders and subsequently adjusted for. It has been well-documented that despite 
ACOG guidelines and proven evidence of effect, many women do not receive treatment with 17-
OHPC, regardless of a history of spontaneous preterm birth and accessibility [64, 65]. Research 
has indicated that treatment with 17-OHPC is lower in women with later gestational ages of 
previous preterm deliveries and in those whose penultimate pregnancy ended in a term delivery 
[64, 65]. These results suggest that these factors, potentially in addition to others, may then be 
associated with both exposure and outcome and are therefore critical confounders of the 17-
OHPC and recurrent birth relationship. This bias is of critical importance in retrospective studies 
that include both treated and untreated women who are not randomized [60].  
In regards to obstetric history as the exposure of interest, there are likely numerous 
factors that contribute to both the previous and recurrent spontaneous preterm delivery that 
remain unidentified. The undefined pathophysiology of preterm birth makes it challenging to 
identify shared causes of each delivery. This is a limitation that exists in all retrospective studies 
on this topic, but can be addressed by using a probabilistic bias analysis for unmeasured 
confounding. It is important to note that it may not be prudent to eliminate the effects of these 
other unknown characteristics, but rather identify which of those factors are shared to determine 
the mechanisms through which preterm birth may be occurring. We will address the biases 
introduced by these commonly ignored characteristics through our model building 
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approaches including all available potential confounders identified a priori through direct 
acyclic graphs in our original model [66].  
Finally, observational studies focused on efficacy of 17-OHPC are limited by 
documentation of compliance with the intensive weekly regimen. 17-OHPC is administered 
as a weekly intramuscular injection initiated between 160 and 206 weeks’ gestation and continued 
until 37 weeks or delivery, whichever occurs first. The injections cause local pain at the site of 
injection in more than 30% of women receiving treatment (Makena Package Insert). This 
burdensome treatment regimen along with frequent side effects often decreases compliance. In 
many observational studies the adherence to treatment is not recorded, particularly in women 
who administer injections at home. We will overcome this limitation in our work by utilizing 
data from a RCT with detailed information on adherence to the treatment regimen, 
allowing us to limit the cohort to those with >50% compliance.  
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3.1 ABSTRACT 
Background Our objective was to estimate the association between methadone and neonatal 
abstinence syndrome (NAS) compared with buprenorphine using a probabilistic bias analysis to 
account for unmeasured confounding by severity of addiction. 
Methods We used a cohort of live-born infants exposed in utero to methadone or buprenorphine 
for maternal opioid maintenance therapy at Magee-Womens Hospital in Pittsburgh, PA from 
2013‒2015 (n=716). Exposure and outcome status were determined using pharmacy billing 
claims. Log-binomial regression models were used to assess the association of treatment with 
NAS after adjusting for parity, maternal race, age, delivery year, employment, hepatitis C, 
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smoking, marital, and insurance status. We implemented a probabilistic bias analysis, informed 
by an internal validation study, to assess the impact of unmeasured confounding by severity of 
addiction. 
Results Infants exposed to methadone in utero were more likely to experience NAS compared 
with those exposed to buprenorphine [RR: 1.3, 95% CI: 1.2, 1.5]. After adjustment, infants 
exposed to methadone were 30% (adjusted RR 1.3, 95% CI: 1.1, 1.5) more likely than infants 
exposed to buprenorphine to have NAS. In the validation cohort (n=200), severe addiction was 
more common in the methadone- compared with buprenorphine-exposed deliveries (77% vs. 
32%). However, adjustment for severe addiction in the bias analysis only slightly attenuated the 
association (RR 1.2, 95% CI: 1.0, 1.4), supporting the conventional analysis.  
Conclusions Methadone is associated with increased risk of NAS compared with buprenorphine 
in infants exposed in utero. This association is subject to minimal bias due to unmeasured 
confounding by severity of addiction. 
3.2 INTRODUCTION 
Pregnant women are not immune from the opioid epidemic in the U.S.[2, 12, 67, 68] The trend 
of rising opioid use in pregnancy parallels simultaneous increases in the number of cases of 
neonatal abstinence syndrome (NAS). NAS is a clinical condition in which the infants exposed 
to opioids in utero manifest symptoms of withdrawal from the drug postnatally.[22, 69, 70] NAS 
is costly to treat[71] and it has long term sequelae for the child, including neurocognitive and 
behavioral issues[27] along with decreases in visual acuity.[72] To lessen the risk of NAS and a 
host of other poor maternal and child health outcomes, pregnant women with opioid use 
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dependence are treated with either methadone or buprenorphine as opioid maintenance 
therapy.[4] Literature has consistently shown that buprenorphine use is associated with less NAS 
and shorter duration of neonatal treatment compared with the use of methadone.[28, 37-40] 
However, these findings may be biased because large databases often used for this research 
typically do not contain data on the severity of the mother’s addiction—a potential confounding 
variable.[19, 29] 
In the U.S., women who suffer from more severe opioid addiction are often allocated to 
methadone treatment, while women with lower risk of relapse and drug diversion tend to be 
treated with buprenorphine. This prescribing preference exists in part because methadone and 
buprenorphine are delivered with different systems of care in the U.S. Women prescribed 
methadone must attend a clinic daily to obtain medication under direct observation, eliminating 
the chance of diversion. Alternatively, women treated with buprenorphine are legally permitted a 
supply of medication for administration at home through outpatient providers.[18] Therefore, it 
is critical to account for factors that determine this prescribing preference in comparative 
treatment studies. 
Our objective was to estimate the association between methadone versus buprenorphine 
exposure as opioid maintenance therapy and NAS after accounting for unmeasured confounding 
by severity of addiction.   
3.3 METHODS 
We used data on all singleton pregnancies delivered at 20 to 42 weeks of gestation with live-born 
infants exposed to in utero methadone or buprenorphine opioid maintenance therapy at Magee-
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Womens Hospital (MWH) in Pittsburgh, PA from 2013-2015. MWH delivers over 10,000 
infants annually and cares for opioid addicted mothers with treatment protocols similar to those 
at other U.S. institutions.[32, 33, 39, 40] Buprenorphine is administered through prescription by 
a certified buprenorphine provider while methadone treatment requires daily visits to an opioid 
treatment clinic.[73] The protocol is described in detail in the Appendix A. 
International Classification of Diseases, Ninth (ICD-9) and Tenth Revision (ICD-10) 
codes in pharmacy billing claims were used to identify drug-dependent (ICD-9 64831) or drug-
complicated deliveries (ICD-10 O99324). Billing claims that specifically documented exposure 
to methadone or buprenorphine as opioid maintenance therapy were then confirmed with dosing 
information extracted from the medical chart. Buprenorphine-exposed infants were those whose 
mothers were treated with Subutex® (buprenorphine, n=299) (Reckitt Benckiser 
Pharmaceuticals Inc., VA) or Suboxone® (buprenorphine + naloxone, n=10) (Reckitt Benckiser 
Pharmaceuticals Inc., VA). The exposure window of interest was the day of delivery because 
medication effect on NAS is most influential closest to delivery [74] and we lacked access to the 
entire treatment trajectories including treatment initiation dates.  
We identified cases of NAS from pharmacy billing codes indicating treatment with 
morphine after delivery. At MWH, all infants with known or suspected opioid exposure in utero 
are kept for NAS observation for 5 to 7 days. Infants are scored using the Finnegan Scale every 3 
to 4 hours.[24] When the average of 3 consecutive scores is ≥8 on the Finnegan Scale, infants are 
treated with morphine. In our cohort, morphine treatment was highly correlated with ICD code 
indicative of “Drug Withdrawal Syndrome in Newborn” (kappa>0.99). 
Maternal characteristics and birth outcomes were obtained first from the MWH electronic 
pharmacy records comprised primarily of billing and ICD codes, and were informed with data 
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provided by the birth record when data were missing. These data are a combination of self-
report, clinical billing codes, and chart documentation by a health professional. Information on 
maternal race (Black, White, other), education level (less than high school, high school or 
equivalent, some college, college graduate), employment (yes, no), marital status (married, 
unmarried), insurance type (private, public), prepregnancy weight and height, parity, smoking 
during pregnancy (yes, no), and hepatitis C status (positive, negative) were available. Body mass 
index (BMI) was calculated as weight (kilograms) divided by height (meters) squared and was 
categorized as underweight (<18.5), normal weight (BMI 18.5 to <25), overweight (BMI 25 to 
<30), or obese (BMI ≥30).[75]  Birth outcome data included gestational age at delivery, infant 
length of stay (days), birthweight, congenital anomalies (yes, no), admission into the NICU (yes, 
no), and number of prenatal visits. Gestational age was determined using the best obstetric 
estimate in the chart from ultrasound or last menstrual period when ultrasound was not available. 
This study was approved by our Institutional Review Board. 
3.3.1 Validation Cohort 
Severity of addiction is a potential confounder that was unmeasured in our dataset. We therefore 
performed a validation study to collect indicators of addiction severity from medical chart 
abstraction on a random sample of 100 buprenorphine- and 100 methadone- treated women in 
our cohort. The study team identified four indicators of severity of addiction that were based on 
literature [19, 29, 34, 76] and clinical expertise (details in Appendix A). One reviewer (LSL), 
who was blinded to outcome but not exposure status, performed the medical chart abstractions 
and entered data into an electronic database. The majority of information was abstracted from 
physicians’ notes and the social workers’ discharge plans.  
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We defined severe addiction as having any one of the 4 following indicators documented 
in the chart: 1) conversion to opioid maintenance therapy during pregnancy, 2) documented 
relapse during pregnancy, 3) use of illicit substances at delivery, and 4) use of benzodiazepines 
in pregnancy. When there was no documentation of conversion to opioid maintenance therapy in 
the chart, women were assumed to have conceived on the same treatment noted at delivery. All 
other lack of documentation was recorded as missing unless explicitly noted that the patient did 
not have the indicator (e.g. “patient did not relapse in this pregnancy”). Reconversion to therapy 
within one pregnancy was recorded as a relapse. Illicit substance use at the time of delivery 
included any of the following: marijuana, benzodiazepines, illicit buprenorphine, cocaine, 
nondescript intravenous drugs, heroin, or illicit opiate pills.  
3.3.2 Statistical Analysis 
Multivariable log-binomial regression models were used to estimate the independent association 
between NAS and methadone compared with buprenorphine while accounting for clustering 
within each woman (25 contributed multiple pregnancies).[77] We calculated risk ratios (RR), 
risk differences (RD), and their 95% confidence intervals (CI). Risk differences were calculated 
using marginal standardization.[78] We identified potential confounders a priori using theory-
based conceptual models: maternal indication for opioid maintenance therapy, gestational age at 
opioid maintenance therapy initiation, duration of opioid dependence, maternal age, race, 
employment status, smoking status, marital status, insurance type, hepatitis C status, parity and 
year of delivery. The final model was limited to maternal age, race, employment status, smoking 
status, marital status, insurance type, hepatitis C status, parity and year of delivery, based on 
availability of data. We did not adjust for adequacy of prenatal care, total visits to the emergency 
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room during the pregnancy, and gestational age because they are likely on the causal 
pathway.[29] 
 
Probabilistic Bias Analysis 
To quantify the extent to which unmeasured confounding by severity of addiction biased the 
association between opioid maintenance therapy and NAS, we performed a probabilistic bias 
analysis. This approach is based on a set of methods developed and described in detail previously 
by Lash et al.[79, 80] The parameters for this analysis were informed using data indicative of 
addiction severity from our internal validation study. We defined the limits of the relative risk 
due to confounding using the Flanders and Khoury method.[81] This method involved fitting two 
logistic regressions in the subcohort: the first modeling the odds of treatment type by severity of 
addiction, the second modeling the odds of NAS by severity of addiction. The Flanders and 
Khoury method also incorporates the prevalence of severity in each treatment group (Appendix 
A). This information was used to determine the limits of the trapezoidal distribution used to 
parameterize the risk. We sampled the risk due to confounding from 100,000 simulated data sets 
using a Monte Carlo approach. Results were presented as bootstrapped point estimates with an 
interval defined as the 2.5th and 97.5th percentiles. This interval corresponds to the 95% 
confidence interval obtained in a conventional analysis but incorporates both systematic and 
random error. The results from the probabilistic bias analysis were then compared with the risk 
ratios and 95% confidence intervals from the conventional model.  
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3.4 RESULTS 
There were a total of 872 drug-dependent pregnancies in the study period. Of these, 745 (85%) 
received either methadone or buprenorphine as opioid maintenance therapy on the day of 
delivery and were eligible for this study (Figure 1). We excluded 9 women with multi-fetal 
gestations (18 infants), 6 with a fetal death, and five who had stopped all medication due to 
relapse or weaning prior to delivery. Our final sample consisted of 716 pregnancies.  
 Slightly more than half of pregnancies on opioid maintenance therapy were treated with 
methadone (57%) and the remaining with buprenorphine (43%). Women treated with methadone 
were more likely than their buprenorphine-treated counterparts to be unmarried, unemployed, 
hepatitis C positive, multiparous, and to have less than a high school education (Table 1). 
Methadone-treated pregnancies on average had shorter gestations and infants with lower 
birthweights. Race, age, prepregnancy BMI, and smoking status were not meaningfully different 
between treatment groups. 
NAS occurred in 58% of the infants (n=415). Infants with treatment for NAS were more 
likely to be born to unmarried, unemployed, hepatitis C positive mothers with less than a high 
school education and a normal prepregnancy BMI (Appendix A: Table 12). Infants diagnosed 
with NAS were also more likely to be born at a later gestational age without a congenital 
anomaly compared with their counterparts not requiring treatment.  
The incidence of NAS was 65% in infants exposed in utero to methadone compared with 
49% in infants exposed to buprenorphine. Infants exposed to methadone in utero were 30% more 
likely than infants exposed to buprenorphine to be treated for NAS (unadjusted RR 1.3, 95% CI: 
1.2, 1.5).  After adjustment for parity, maternal race, employment status, hepatitis C status, age, 
year of delivery, smoking status, marital status, and insurance, the association did not change 
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(adjusted RR 1.3, 95% CI: 1.1, 1.5). On the absolute scale, the adjusted RD was 0.14 (95% CI: 
0.059, 0.22), indicating that methadone was associated with 14 excess cases of NAS for every 
100 live-born infants born to mothers treated with methadone compared with buprenorphine 
(Table 3).   
Though there were expected significant differences comparing the study cohort of opioid 
dependent mothers to all births at MWH from 2013-2014 (Appendix A: Table 10), the validation 
subsample was similar to the full study cohort (Appendix A: Table 11). In the validation 
subsample, methadone-treated women were more likely than buprenorphine-treated women to 
have converted to opioid maintenance treatment during pregnancy (58% vs 12%; median 
gestational age at conversion: 12 weeks vs before conception), relapsed in pregnancy (23% vs 
4%), used any illicit substance at delivery (24% vs 15%), or used benzodiazepines during 
pregnancy (28% vs 8%) (Table 4). Prevalence of having any one of the indicators of severe 
addiction was higher in the methadone group compared with buprenorphine (77% vs. 32%). This 
composite of addiction severity was associated with a slightly higher risk of NAS (odds ratio 1.2, 
95% CI: 0.7, 2.1). These results were robust to removal of each individual factor included in the 
severity index (data not shown). 
There was a large amount of missing data in the validation cohort that varied by 
treatment (Appendix A: Table 13). Women treated with buprenorphine were more likely than 
methadone-treated women to have missing data for more than one indicator of severity. Despite 
the difference in rate of missing data, women treated with buprenorphine also had documentation 
indicating less severity (e.g. “patient did not relapse in pregnancy”) more often than methadone-
treated women. This is true for each severity indicator excluding benzodiazepine use (Table 4).  
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After accounting for unmeasured confounding by severity of addiction in the 
probabilistic bias analysis, the association between methadone and NAS was slightly attenuated 
from the conventional results [point estimate 1.2 (95% simulation interval: 1.0, 1.4; Table 5)]. 
The bootstrapped 5th and 95th percentiles in the bias analysis were slightly wider than the 
conventional confidence intervals as they accounted for both systematic and random error.  
3.5 DISCUSSION 
There is agreement in the literature that buprenorphine confers benefits over methadone for 
opioid maintenance therapy in pregnancy, including decreased risk of NAS in the infants 
exposed in utero.[19, 37, 39, 40] Nonetheless, there is a potential for these findings to be biased 
due to unmeasured confounding.[19, 29] Our conventional analysis results suggested that the risk 
of NAS in infants exposed to in utero methadone was 30% higher compared with buprenorphine-
exposed infants. The results from the probabilistic bias analysis suggest that unmeasured 
confounding by severity of addiction only slightly biased the conventional results away from the 
null. Although we found that women receiving methadone had more indicators of severe 
addiction than women receiving buprenorphine, the relatively weak relationship between 
addiction severity and NAS reduced the potential for prescribing differences to confound the 
primary association. 
The ideal approach to eliminate unmeasured confounding is to conduct a randomized 
controlled trial. However, the largest double-blinded, flexible-dosing, randomized controlled trial 
comparing methadone and buprenorphine use in pregnancy (Maternal Opioid Treatment: Human 
Experimental Research trial) was plagued with the same biases faced in observational 
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research.[28] Analyzing only women who remained on randomized treatment, Jones et al.[28] 
found no significant difference in percent of infants requiring treatment for NAS between 
treatment groups, though more morphine (mean dose 10.4 vs. 1.1 mg) and longer hospital stays 
(17.5 vs. 10.0 days) were needed for infants exposed to methadone in utero. Importantly, 
investigators found that 33% of women randomized to buprenorphine discontinued treatment, 
with 71% of them reporting “dissatisfaction” with treatment. This is in stark contrast to only 18% 
of methadone patients discontinuing treatment, of whom only 13% reported “dissatisfaction” 
with treatment. Only those women who continued allocated treatment were included in the final 
analyses. Furthermore, despite randomization, women who remained on methadone treatment 
had longer cumulative lifetime drug use. Together, these findings demonstrate a similar bias to 
unmeasured confounding as addiction severity may have influenced treatment choice and 
continuation regardless of randomization.  
Our results are consistent with a large meta-analysis of 11 studies including 855 
methadone-treated women and 515 buprenorphine-treated women for opioid dependence and 
risk of NAS.[19] These authors described a summary estimate of 1.11 (95% CI: 1.02, 1.23) 
reported as an increased risk of NAS by 10% in infants exposed to methadone compared with 
buprenorphine in utero. The authors conducted a sensitivity analysis for unmeasured 
confounding by indication applying the VanderWeele and Arah [82] approach for unmeasured 
confounding. Unlike our analysis, which was informed by an internal validation study, these 
authors used bias parameters informed by the extant literature. They found that after accounting 
for unmeasured confounding by indication, the risk of NAS associated with methadone treatment 
in the conventional analysis was biased away from the null (50th percentile adjusted RR 1.01, 
95% CI: 0.92, 1.11). Consistent with our conceptual model, bias parameters reflected values for 
39 
unmeasured confounding that conferred increased risk for poor neonatal outcomes in the 
methadone treated women [RR of confounder-NAS association (RRCD) 1.05-1.25] that was 
reversed in the buprenorphine patients (RRCD 0.80-0.95). Prevalence of unmeasured confounding 
by indication was assumed to be 40% in both treatment groups. Inputs for this bias analysis have 
been previously questioned as the assumptions informing these are subjective and results vary by 
slight changes in their inputs.[31] Our findings extend this work by using an internal validation 
study to inform the bias parameters and draw conclusions from one study center limiting 
heterogeneity in treatment practices. Using more conservative bias parameters informed from the 
validation cohort slightly weakened the impact of unmeasured confounding on our results by 
comparison.  
In our probabilistic bias analysis, informed from the validation cohort, the RR for NAS 
associated with methadone compared with buprenorphine marginally decreased from 1.3 (95% 
CI: 1.1, 1.5)  to 1.2 (95% CI: 1.0, 1.4) when limits were defined by the Flanders and Khoury 
method.[81] We therefore maintain that the risk of NAS associated with methadone treatment 
even after accounting for severity, may not be fully explained by unmeasured confounding. 
It was surprising that accounting for severity of addiction did not further attenuate the 
association between methadone treatment and NAS compared with buprenorphine. However, the 
impact of addiction severity on the association between opioid maintenance therapy and NAS is 
likely limited by the weak relationship between addiction severity and NAS. Of note, women 
actively abusing heroin during pregnancy have a lower risk of NAS compared with women 
receiving methadone as replacement therapy.[37, 83] Therefore, behaviors associated with more 
severe addiction such as relapse and later conversion to opioid maintenance therapy may not 
increase the risk of NAS. It is important to note that the lower risk of NAS with active abuse 
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does not negate other potential risks such as reduced prenatal care. Opioid maintenance therapy 
should undoubtedly remain the standard care.[4, 84] 
Our findings must be interpreted within the bounds of their limitations. We used a large 
administrative database that lacked detailed information on treatment and addiction histories. 
Without information on the initiation, timing, and duration of exposure to medication, we were 
unable to appropriately assess how these factors influence the development of NAS. We relied 
on the dose and medication treatment on the day of delivery as a relatively crude measure of 
exposure, as it is thought that treatment closest to the time of delivery has the strongest impact on 
NAS.[74] Though using this approach allows for misclassification of exposure, this unlikely 
impacts our findings as only 6 of 200 women in our validation cohort had documentation of ever 
changing treatment (inclusive of prior to pregnancy). The lack of information on addiction 
history contributes considerably to the unmeasured confounding remaining in the analysis. 
Furthermore, by using treatment for NAS as our outcome measurement, we restricted our 
analysis to only the more severe cases of NAS. Though having a gradient of Finnegan scores or 
morphine dose may be informative, those receiving treatment incur the largest costs and this 
approach is subject to less misclassification due to the subjectivity of the Finnegan Scale.  
The lack of adjustment for prescribing preferences by severity of addiction, which is 
typically unmeasured, is one of the greatest shortcomings in the current literature. Our 
probabilistic bias analysis aimed to minimize this limitation using information from our internal 
validation cohort. As was expected due to the nature and sensitivity of this topic, upon chart 
review there was a substantial amount of missing data in the validation cohort with a missingness 
that differed by opioid maintenance type. Differential missingness was likely driven by more 
buprenorphine treated patients entering into pregnancy on treatment and potentially having less 
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interaction with the healthcare system due to an overall superior health profile. Both may 
contribute to less documentation in their charts. Though we are the first to use an internal 
validation cohort to derive information on severity to adjust for unmeasured confounding, our 
findings are subject to the limitations of the data available to us and to the parameterization the 
severity index. Future research with the aim of developing a robust severity index or using a 
clinically validated scale is warranted. Nevertheless, this approach is preferable to deriving effect 
estimates exclusively from the literature.  
Prescribing preferences for opioid maintenance therapy are often warranted as many 
women benefit from the different methods of delivery of care in the U.S. However, in many 
places in the U.S. patients do not have access to both treatment options due to both a lack of 
clinics and licensed providers in addition to limitations imposed by insurance. Lack of treatment 
options can result in structural confounding in other studies. In our study population, it is 
unlikely that non-positivity impacted our results as women had access to both treatment options 
and both were covered under Pennsylvania Medicaid, the primary insurer of this population. 
 As both observational studies and randomized trials are subject to the biases inherent in 
opioid maintenance treatment choices, it is imperative to account for this unmeasured 
confounding when comparing methadone with buprenorphine exposures in pregnancy to 
advocate for availability of both options if one is superior. Our results suggest that the previous 
findings that buprenorphine is associated with less NAS compared with methadone in infants 
exposed in utero are subject to minimal bias from unmeasured confounding. Applying similar 
bias analyses to the association of these treatments with other neonatal outcomes is necessary to 
fully inform treatment decisions. 
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3.6 TABLES AND FIGURES 
Table 1. Maternal Characteristics by Opioid Maintenance Treatment Type, Magee-
Womens Hospital, 2013- 2015 (n=716). 
Characteristic Methadone 
N (%) 
n=407 
Buprenorphine 
N (%) 
n=309 
Race 
   White 
    Black 
    Missing 
 
381 (93.6) 
19 (4.7) 
7 (1.5) 
 
294 (95.1) 
8 (2.6) 
7 (2.3) 
Mother’s age [Mean (SD)] 29.1 (4.7) 28.5 (4.9) 
Mother’s Education 
    Less than high school 
    High school graduate or GED completed 
    Some college credit 
    College graduate 
    Missing 
 
83 (20.4) 
165 (40.5) 
78 (19.2) 
66 (16.2) 
15 (3.7) 
 
45 (14.6) 
139 (45.0) 
68 (22.0) 
54 (17.4) 
3 (1.0) 
Prepregnancy BMI [Mean (SD)]a 24.6 (5.3) 24.2 (6.1) 
BMI categoryb 
    Underweight (<18.5kg/m2) 
    Normal weight 
    Overweight 
    Obese 
    Missing 
 
11 (2.7) 
116 (28.5) 
35 (8.6) 
29 (7.1) 
216 (53.1) 
 
17 (5.5) 
94 (30.4) 
30 (9.7) 
24 (7.7) 
144 (46.6) 
Married 35 (8.6) 58 (18.8) 
Employed 139 (34.2) 135 (43.7) 
Smoked during pregnancy 336 (82.6) 250 (80.9) 
Parity  
    Nulliparous 
    1-2 previous pregnancies 
    Greater than 2 pregnancies 
 
118 (29.0) 
208 (51.1) 
81 (19.9) 
 
106 (34.3) 
151 (48.9) 
52 (16.8) 
Hepatitis c positive 61 (15.0) 31 (10.0) 
Gestational age at delivery [Mean (SD)] 37.4 (2.9) 38.5 (2.5) 
Birthweight [Mean (SD)] 2734 (619.3) 2999 (591.2) 
Infant with congenital anomaly 50 (12.3) 27 (8.7) 
aPrepregnancy BMI based on n=356. 
bPrepregnancy BMI defined as underweight (<18.5 kg/m2), normal weight (18.5 to <25 kg/m2), 
overweight (25 to <30 kg/m2), obese (≥30 kg/m2). 
GED=general education development, SD=standard deviation, BMI=body mass index 
 
43 
Table 2. Maternal Characteristics by Opioid Maintenance Treatment Type in a Validation 
Subcohort, Magee-Womens Hospital, 2013-2015 (n=200). 
Characteristic Methadone 
N (%) 
n=100 
Buprenorphine 
N (%) 
n=100 
Race 
   White 
    Black 
    Missing 
 
97 
3 
0 
 
97 
2 
1 
Mother’s age [Mean (SD)] 28.6 (5.1) 28.2 (5.2) 
Mother’s Education 
    Less than high school 
    High school graduate or GED completed 
    Some college credit 
    College graduate 
    Missing 
 
19 
40 
23 
14 
4 
 
9 
52 
18 
19 
2 
Prepregnancy BMI [Mean (SD)]a 24.6 (5.9) 23.7 (5.3) 
Married 8 21 
Employed 31 43 
Smoked during pregnancy 84 80 
Parity  
    Nulliparous 
    1-2 previous pregnancies 
    Greater than 2 pregnancies 
 
31 
47 
22 
 
39 
46 
15 
Hepatitis c positive 12 10 
Gestational age at delivery [Mean (SD)] 37.3 (3.2) 39.1 (1.8) 
Birthweight [Mean (SD)] 2695 (631.6) 3147 (472.4) 
Infant with congenital anomaly 15 10 
Severe maternal addiction 77 32 
aPrepregnancy BMI based on n=43 in methadone treated women and n=54 in buprenorphine 
treated women. 
GED=general education development, SD=standard deviation, BMI=body mass index 
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Table 3. Results from conventional analyses of the risk of neonatal abstinence syndrome 
associated with methadone compared with buprenorphine as opioid maintenance therapy, 
at Magee-Womens Hospital, Pittsburgh, Pennsylvania (2013-2015). 
Opioid 
maintenance 
therapy 
Events 
(n) 
Population 
at risk 
Unadjusted 
risk per 
100 
livebirths 
Unadjusted risk difference 
per 100 live-born infants  
(95% confidence interval) 
Adjusteda risk difference 
per 100 live-born infants 
(95% confidence interval) 
Buprenorphine 
Methadone 
152 
263 
309 
407 
49 
65 
Reference 
15 (8.1, 23) 
Reference 
14 (5.9, 22) 
    Unadjusted relative risk 
(95% confidence interval) 
Adjusteda relative risk 
(95% confidence interval) 
Buprenorphine 
Methadone 
   Reference 
1.3 (1.2, 1.5) 
Reference 
1.3 (1.1, 1.5) 
aAdjusted for parity, maternal race, employment status, hepatitis c status, age, year of delivery, 
smoking status, marital status, and insurance. 
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Table 4. Characteristics of a subsample of opioid use dependent singleton pregnancies with 
severity of addiction indicators abstracted from medical charts at Magee-Womens Hospital 
in Pittsburgh, 2013-2015 (n=200). 
Characteristic Methadone 
n=100 
Buprenorphine 
n=100 
Converted to opioid maintenance therapy in pregnancy 
     Yes 
     No 
     Missing 
 
58 
18 
24 
 
12 
30 
58 
Gestational age at conversion (Median, IQR), weeks 12 (5, 22) Prior to conception (prior, 4) 
Relapse in pregnancy 
     Yes 
     No 
     Missing 
 
23 
9 
68 
 
4 
24 
72 
Using illicit substance at time of delivery 
     Yes 
     No 
     Missing 
 
24 
34 
42 
 
15 
71 
14 
Used benzodiazepines in pregnancy 
     Yes 
     No 
     Missing 
 
28 
33 
39 
 
8 
22 
70 
Neonatal abstinence syndrome 
                Yes 
    No 
 
61 
39 
 
54 
46 
IQR=interquartile range 
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Table 5. Comparison of results from adjusted conventional and probabilistic bias analyses 
accounting for unmeasured confounding by severity of addiction on the risk of neonatal 
abstinence syndrome associated with methadone compared with buprenorphine as opioid 
maintenance therapy, at Magee-Womens Hospital, Pittsburgh, Pennsylvania (2013-2015). 
Opioid 
maintenance 
therapy 
Conventional analysis: 
Adjusteda relative risk 
(95% confidence 
interval) 
Bias Analysis 1:  
Adjusteda point estimate  
(95% bootstrapped 
simulation interval)b 
Buprenorphine 
Methadone 
Reference 
1.3 (1.1, 1.5) 
Reference 
1.2 (1.0, 1.4) 
aAdjusted for parity, maternal race, employment status, hepatitis c status, age, year of delivery, 
smoking status, marital status, and private vs. public insurance. 
bminimum RRC=1.0, mode 1=1.02, mode 2=1.11, maximum RRC=1.13 
RRc=relative risk due to confounding 
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Figure 1. Flow diagram describing sample population (n=716, 2013-2015*Note: 25 women 
with 2 pregnancies). 
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4.1 ABSTRACT 
Background Pregnant women treated with methadone as opioid maintenance therapy are more 
likely than women treated with buprenorphine to deliver preterm. Preterm birth is associated 
with less risk of neonatal abstinence syndrome (NAS). We sought to assess the role of preterm 
birth as a mediator of the relationship between in utero exposure to methadone and NAS 
compared with buprenorphine.  
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Methods We studied 716 women receiving methadone or buprenorphine as opioid maintenance 
therapy and delivering live-born infants at Magee-Womens Hospital, Pittsburgh, Pennsylvania 
(2013-2015). We implemented inverse probability weighted marginal structural models to isolate 
the role of preterm birth (≤37 weeks’ gestation). Weights accounted for confounding by maternal 
age, race, insurance, parity, delivery year, marital, employment, hepatitis C, and smoking status. 
Results Approximately 57% of the cohort was treated with methadone. Preterm birth was more 
common in methadone exposed pregnancies (25% vs. 14%). The incidence of NAS was higher 
in methadone-compared with buprenorphine-exposed infants (65% vs 49%), and term compared 
with preterm births (64% vs 36%). For every 100 infants live-born to mothers treated for opioid 
dependence, there were 13 excess cases of NAS among infants exposed to methadone compared 
with buprenorphine [adjusted RD=13.3, 95% CI: (5.7, 20.9)]. Among term births, this increased 
to 17 excess cases of NAS in methadone- compared with buprenorphine-exposed [16.7 (9.3, 
24.0)]. Findings were similar on the relative scale.  
Conclusion The further increased risk of NAS associated with methadone use versus 
buprenorphine in term deliveries emphasizes the utility of buprenorphine in clinical settings 
aimed at decreasing NAS. 
4.2 INTRODUCTION 
Neonatal abstinence syndrome (NAS), or postnatal opioid withdrawal, affected nearly 6 of every 
1,000 live-born U.S. infants in 2012 [85]— a five-fold increase since 2000 [21]. NAS is 
associated with long-term physical and behavioral complications [27], and cost the U.S. health 
system an estimated $1.5 billion in 2012 alone [85]. The marked increase in NAS parallels 
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increases in opioid use dependence in pregnancy [14] and use of the two recommended opioid 
maintenance therapies, buprenorphine and methadone [4]. Determining which treatment regimen 
will optimize maternal and infant outcomes, including reducing risk of NAS, is a public health 
priority. 
Literature suggests that buprenorphine is associated with superior perinatal outcomes 
compared with methadone, most notably reporting less NAS and shorter duration of neonatal 
treatment [17, 19, 28, 86]. Though the majority of extant studies agree, methadone remains the 
mainstay of care in the U.S. [87] and barriers to access buprenorphine treatment persist [88]. 
Prescribing of buprenorphine as opioid maintenance therapy in an outpatient setting requires that 
the physician obtain a waiver from the Controlled Substances Act [89]. In 2012, only 2.2% of all 
physicians in the U.S. received the waiver and were able to treat patients with buprenorphine 
[90]. 
Inherent biases in prescribing preferences, access to treatment options, and necessity of 
tailoring treatment to the individual beyond risk of NAS, have continued to fuel the debate on 
optimal treatment in pregnancy. The role of gestational age in the relationship between opioid 
maintenance therapy and NAS, however, has not been investigated. Ignoring or mishandling 
gestational age is a problem frequently encountered in perinatal epidemiologic studies [41]. 
Researchers frequently adjust for gestational age in regression models or ignore its impact 
altogether. Such approaches ignore the complexities of this relationship. Methadone treatment 
has been associated with an increased risk of preterm birth compared with buprenorphine 
treatment or no treatment [17, 43] [37, 39, 44], and preterm infants exhibit a lower incidence and 
reduced severity of NAS compared with term infants [45-47]. Prematurity is likely a mediator of 
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this relation, so the estimated increased risk of NAS associated with methadone compared with 
buprenorphine may be an underestimate among term infants- the ideal gestational length.  
In this study, we aimed to estimate the association between opioid maintenance therapy 
and NAS, independent of the effect of opioid maintenance therapy on prematurity. We 
hypothesized that the increased risk of NAS associated with methadone exposure compared with 
buprenorphine would be stronger among term than preterm births. If true, these results will 
support the expansion of buprenorphine use and access in pregnancy, making more treatment 
options available to individualize treatment.  
4.3 METHODS 
Magee-Womens Hospital is one of the largest maternity hospitals in Pennsylvania with 
approximately 10 000 deliveries annually. Pregnant women initiating new opioid maintenance 
therapy at Magee-Womens Hospital can self-select treatment with methadone or buprenorphine 
in accordance with the American Congress of Obstetricians and Gynecologists recommendations 
provided they meet prescribing requirements for both [4]. Women who conceive while receiving 
opioid maintenance therapy are normally maintained on their medication regimen. 
Study cohort 
The study cohort consisted of all live-born, singleton deliveries to women exposed to 
methadone or buprenorphine as opioid maintenance therapy on the day of delivery at Magee-
Womens Hospital from 2013-2015. Using International Classification of Diseases, Ninth and 
Tenth Revision codes for drug- dependent (ICD-9 64831) or drug- complicated delivery (ICD-10 
O99324) we identified 872 drug-dependent pregnancies (Figure 1). Of these, 745 had 
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documentation of opioid maintenance therapy with either buprenorphine or methadone on the 
day of delivery. We restricted the cohort further to live-born, singleton pregnancies and therefore 
excluded 6 fetal deaths and 9 pairs of twins. We retained 716 pregnancies (691 women) in our 
final analytic sample. The Institutional Review Board at the University of Pittsburgh approved 
this study.  
 
Opioid maintenance medications 
We determined maternal exposure to opioid maintenance therapy with pharmacy billing claims, 
then extracted dosing information directly from the medical chart. Women treated with 
Subutex® (buprenorphine, n=299) (Reckitt Benckiser Pharmaceuticals Inc., VA) or Suboxone® 
(buprenorphine + naloxone, n=10) (Reckitt Benckiser Pharmaceuticals Inc., VA) were 
considered buprenorphine-treated. In utero exposure to buprenorphine was the referent in all 
analyses. We selected treatment on the day of delivery as the exposure of interest and used this 
as a surrogate of pregnancy exposure as opioid exposure closest to the time of delivery is thought 
to have the highest impact on NAS risk [74] and we lacked data on entire treatment trajectories.  
 
Neonatal abstinence syndrome 
We identified cases of NAS using pharmacy-billing codes indicating infant pharmacologic 
treatment with morphine. At Magee-Womens Hospital all infants with known exposure to 
opioids, both illicit and maintenance, remain in the hospital for 5 to 7 days post-delivery for 
continuous monitoring for NAS. Infants are scored using the Finnegan Neonatal Abstinence 
Scoring Tool [24] every 3 to 4 hours; those with an average score of eight or greater for 3 
consecutive assessments receive treatment with morphine. In our cohort, receipt of morphine was 
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highly correlated with ICD code indicating “Drug Withdrawal Syndrome in Newborn” 
(kappa>0.99).  
 
Preterm birth 
Preterm birth was the mediator in each analysis. For consistency with the literature, we defined 
preterm birth as live-born delivery prior to 37 weeks gestation documented in the pharmacy 
billing records [91]. We were unable to discern between spontaneous and induced labor and 
therefore considered both in our definition of preterm birth. Gestational age was determined 
using the best obstetric estimate from ultrasound or last menstrual period when ultrasound was 
unavailable. All pregnancies had documented gestational age from 20 to 42 weeks at delivery.  
Preterm birth meets the criteria as a potential mediator of the association between opioid 
maintenance therapy and NAS as: 1) methadone has been shown to be associated with preterm 
birth both in comparison to buprenorphine [17, 39, 44] and to no opioid maintenance therapy 
[37, 43], and 2) preterm infants develop less, or less severe, NAS compared with term infants 
after exposure to methadone [45-47, 92].  
 
Covariates  
We obtained data on medication use, maternal characteristics and pregnancy outcomes from 
electronic pharmacy records at Magee-Womens Hospital. Information missing from electronic 
pharmacy records was informed directly from patient charts and birth certificates. Data were 
therefore a combination of clinical billing codes, documentation by a health professional, and 
self-report.  
Maternal characteristics in our cohort included maternal age, race (Black, White, other), 
education (less than high school, high school graduate or equivalent, some college, college 
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graduate), marital status (yes/no), employment status (employed vs unemployed), type of 
insurance (private vs public), and prepregnancy body mass index (BMI). BMI was calculated as 
prepregnancy weight in kilograms divided by height in meters squared and was categorized as 
underweight (BMI <18.5), normal weight (BMI 18.5 to <25), overweight (BMI 25 to <30), or 
obese (BMI ≥30) [75].  Data pertinent to the pregnancy included parity, hepatitis c status 
(positive vs negative), smoking status (smoked at any point in pregnancy), birthweight, 
congenital anomalies, and year of delivery.  
 
Statistical analysis 
Our analytic strategy was to assess the total adjusted association between opioid maintenance 
therapy and NAS, then to define the controlled direct effect of treatment on NAS removing the 
effect of preterm birth [93]. The difference between these associations represented the effect of 
preterm birth.  
Conceptual models were used to identify potential confounders of the overall relationship 
between opioid maintenance therapy and NAS, and of the preterm birth-NAS association [66]. 
Variables identified as potential confounders of the opioid maintenance therapy-NAS total 
association in our cohort included maternal age, race, marital status, employment status, type of 
insurance, parity, hepatitis c status, smoking status, and year of delivery. Final models of the 
preterm birth- NAS association were adjusted for parity, maternal race, age, smoking status, and 
marital status. 
We first assessed interactions between treatment and preterm birth. Log-binomial models 
regressing NAS against treatment (methadone vs buprenorphine) were performed with and 
without main effect and interaction terms for preterm birth. Because the risk ratio changed by 
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less than 10% with the inclusion of the interaction term, interaction between exposure and 
mediator was considered insignificant and was not included in the final models.  
Our primary analysis evaluating mediation by preterm birth, adjusted for confounders 
marginally using inverse probability weighting [93]. This approach can estimate direct effects in 
the presence or absence of exposure-induced mediator-outcome confounding. To execute this 
analytic approach, we used two log-binomial regression models weighted by stabilized inverse 
probability weights. The weights were generated from modeling methadone exposure then 
preterm birth as a mediator. Weights were calculated as: 
 
where X denotes treatment (X=1 if methadone, X=0 if buprenorphine), M represents 
gestational age (M=1 if term birth, M=0 if preterm birth), y indicates NAS (y=1 if infant treated 
for NAS, y=0 no treatment for NAS), and C represents potential confounders included in the 
model (described above). The numerators represent the predicted probabilities from logistic 
regression models of treatment and preterm birth and the denominators replicate this model but 
adjusted for the confounding variables. All weights had a mean of one with no extreme values.  
Weights were then incorporated into two binomial regression models: 1) modeling the 
total effect of methadone treatment on NAS compared with buprenorphine, 2) the controlled 
direct effect of methadone on NAS among term births. Results were reported on both the risk 
difference (RD) and risk ratio (RR) scale. Standard errors were obtained using robust variance 
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estimators [77]. Finally, the proportion increase in the association in term births was calculated 
as the absolute value of: [(Total Effect-Controlled Direct Effect)/Total Effect] x 100 [94]. 
To triangulate our results, we then implemented a mediation analysis conditionally 
adjusting for the same variables using the generalized product method [95]. While this approach 
can accommodate exposure-mediator interactions, it cannot account for mediator-outcome 
confounders affected by the exposure. However, our conceptual models suggested that no such 
mediator-outcome confounders were present, and our analyses suggested no exposure-mediator 
interactions. Therefore, the generalized product method should yield results identical to the 
inverse probability weighted approach. All analysis was conducted in Stata Version 14 
(StataCorp, College Station, TX).  
4.4 RESULTS 
In the cohort, 57% (n=407) women were treated with methadone and the remaining 43% (n=309) 
with buprenorphine on the day of delivery. Nearly 20% of the final sample was born preterm, 
and 58% developed NAS. Women with a preterm delivery were more likely than women with a 
term delivery to have less than a high school education, smoke during pregnancy, have a higher 
parity (Table 6). Race, maternal age, prepregnancy BMI, marital, employment, and hepatitis C 
status were not different between groups. The preterm infants were lighter at birth and more 
often had a birth defect than infants delivered at term. The incidence of NAS was higher in 
methadone compared with buprenorphine-exposed infants (65% vs. 49%), and term infants 
compared with preterm infants (64% vs. 36%) (Table 7). Rates preterm birth were also higher in 
methadone versus buprenorphine treated women (25% vs. 14%) (Table 7).  
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Crude and adjusted associations between type of opioid maintenance treatment and NAS 
are displayed in Table 8. On the RD scale, for every 100 live-born infants exposed to opioid 
maintenance therapy in utero there were 13 more cases of NAS among infants exposed to 
methadone compared with buprenorphine [RD=13.3, 95% CI: 5.7, 20.9). When the mediating 
role of preterm birth was accounted for, the RD increased to 16.7 (95% CI: 9.3, 24.0). These 
findings suggested an estimated 25% increase in the association among term deliveries.  
Assessing the associations on a relative scale resulted in a total increased relative risk of 
NAS of 1.26 (95% CI: 1.10, 1.45) for women treated with methadone compared with 
buprenorphine. When the mediating role of preterm birth was accounted for, the relative risk of 
NAS increased to 1.34 (95% CI: 1.17, 1.53). The results on the relative scale support the findings 
of an increased risk of NAS with methadone compared with buprenorphine that was stronger 
among term births. Results were not meaningfully different when the generalized product 
method was used to assess mediation (Appendix B: Table 15).  
4.5 DISCUSSION 
Our results support previous findings that risk of NAS is decreased in buprenorphine- compared 
with methadone-exposed infants. We advanced this research by further decomposing the 
association between methadone treatment and NAS compared with buprenorphine and found that 
the association was stronger among term births compared with preterm births. As prolongation of 
pregnancy to term delivery is preferable when possible, this conclusion supports expanded use 
of, and access to, buprenorphine in women eligible for this therapy. 
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Our study expands upon previous work arguing the need to properly address gestational 
age in studying the association between opioid maintenance therapy and NAS [29], by being the 
first to describe the mediating role of preterm birth and to quantify to what extent it may 
influence the association. Regression adjustment for gestational age, an approach often 
implemented in the extant literature [28, 40], is inappropriate. Due to temporality, gestational age 
at delivery is a potential result of opioid maintenance therapy- and cannot be a predictor of 
treatment type.  
As with all studies using observational data, interpreting our associations causally 
requires assumptions of positivity, no interference, exchangeability, and counterfactual 
consistency [96]. In this work, positivity and no interference pose little to no threats to the 
validity of our inferences. Positivity requires the presence of both exposed and unexposed term 
and preterm infants in all confounder strata. This assumption is verifiable, and held in our 
setting, as evidenced by the distribution of our stabilized inverse probability weights. No 
interference requires that the outcome of any given infant is not affected by the opioid 
maintenance therapy or preterm birth status of any other infant, and is a reasonable assumption to 
make. 
Exchangeability requires no uncontrolled information, selection, or confounding bias. As 
with other studies, we were unable to control for the prescribing preference for methadone versus 
buprenorphine. However, our previous work found that unmeasured confounding by severity of 
addiction had little impact on the association between methadone and NAS compared with 
buprenorphine (L. Lemon, University of Pittsburgh, unpublished data). We also lacked 
information on treatment trajectories and gestational age at initiation and therefore assumed that 
treatment remained constant throughout pregnancy. This could introduce immortal time bias if 
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women receiving opioid maintenance therapy were not converted to treatment until after 37 
weeks [42]. However, a detailed chart review we undertook in a subset of this cohort (n=200) 
found that no women were initiated on treatment after 36 weeks (L. Lemon, University of 
Pittsburgh, unpublished data). The absence of trajectories also prohibited the presentation of true 
‘directed’ acyclic graphs. Because data were cross-sectional, we were unable to establish 
temporality of certain associations. For example, it is reasonable to assume that lack of insurance 
could increase a woman’s addiction severity if she cannot afford treatment. Conversely, it is also 
possible that a woman with severe addiction will be less likely to be employed and therefore 
have no insurance. Finally, a lack of treatment history also prevented the evaluation of 
cumulative exposure. If NAS is influenced by a cumulative effect or sensitive exposure window 
we were unable to asses this. We chose to utilize the day of delivery as our exposure of interest 
as complete pregnancy treatment data were unavailable and because this is thought to be the 
most strongly associated with NAS [74].  
A noteworthy limitation of this work is our assumption that the relationships between 
opioid maintenance therapy-preterm birth and preterm birth-NAS are causal. Though a large 
body of work supports the notion that methadone affects preterm birth [17, 37, 39, 43, 44], 
research devoted to better understanding the mechanisms by which gestational age influences 
NAS is needed. Information on this relationship is limited because the pathophysiologic response 
associated with NAS is not fully understood. Preterm infants may experience less NAS due to 
alterations in their opioid receptor network immaturity, differential development of 
neurotransmitters, increased placental transfer of the opioid as pregnancy progresses, less fatty 
tissues available for methadone distribution in preterm infants, and/or less cumulative exposure 
to opioids [23]. However, it should be noted that NAS is defined using Finnegan Scores 
60 
developed in term infants only, and thus, this assessment tool may not be appropriate in preterm 
infants. This complication jeopardizes the validity of the counterfactual consistency assumption, 
an assumption that is commonly violated in studies of preterm birth [97].  
Despite these limitations, our approach is characterized by several strengths. First, we 
found the same results using inverse probability weighted regression and the generalized product 
method, which suggests that our findings are robust to model misspecification. Second, we relied 
on pharmacy records only for identification of women receiving opioid maintenance therapy; 
each treatment type and dose was confirmed by extraction directly from medical records for all 
subjects. Finally, this is the largest study to date that compares these opioid maintenance 
therapies in actively treated pregnant women at one institution in the U.S. 
It is crucial to accurately assess the risk of NAS associated with methadone and 
buprenorphine, while appropriately accounting for gestational age, in order to inform clinical 
practice and guide treatment decisions for pregnant women initiating care. Though previous 
research has established less risk of NAS associated with buprenorphine, we found that the 
increased risk of NAS after methadone exposure in utero compared with buprenorphine was 
stronger among a population of term than preterm births. These results support expanded use of 
buprenorphine as opioid maintenance therapy with the aim of decreasing NAS, adding additional 
incentive to providers and insurance companies to expand access through prescribing availability 
and medication coverage.  
61 
 
4.6 TABLES AND FIGURES 
Table 6. Demographics of women diagnosed with drug-dependent deliveries of singletons 
by preterm vs. term status at Magee-Women Hospital in Pittsburgh, Pennsylvania (2013-
2015, n=716). 
Characteristic Preterm 
N (%) 
n=146 
Term 
N (%) 
n=570 
Opioid maintenance therapy 
    Buprenorphine 
    Methadone 
 
43 (29.5) 
103 (70.5) 
 
266 (46.7) 
304 (53.3) 
Race 
   White 
    Black 
    Other/Unknown 
 
136 (93.2) 
7 (4.8) 
3 (2.0) 
 
539 (94.6) 
20 (3.5) 
11 (1.9) 
Mother’s age [Mean (SD)] 29.2 (4.7) 28.7 (4.8) 
Mother’s education 
    Less than high school 
    High school graduate or GED completed 
    Some college credit 
    College graduate 
    Unknown 
 
35 (24.0) 
52 (35.6) 
34 (23.3) 
20 (13.7) 
5 (3.4) 
 
93 (16.3) 
252 (44.2) 
112 (19.7) 
100 (17.5) 
13 (2.3) 
Prepregnancy BMI [Mean (SD)]a 24.6 (6.5) 24.4 (5.5) 
BMI categorya,b 
    Underweight 
    Normal weight 
    Overweight 
    Obese 
 
5 (7.8) 
38 (59.4) 
21 (32.8) 
8 (5.5) 
 
23 (7.9) 
172 (58.9) 
97 (33.2) 
45 (7.9) 
Married 19 (13.0) 74 (13.0) 
Employed 52 (35.6) 222 (39.0) 
Smoked during pregnancy 129 (88.4) 456 (80.0) 
Parity  
    Nulliparous 
    1-2 previous pregnancies 
 
43 (29.5) 
67 (45.9) 
 
181 (31.8) 
292 (51.2) 
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   Greater than 2 pregnancies 
 
 
 
36 (24.6) 
 
 
 
97 (17.0) 
Hepatitis C positive 15 (10.3) 77 (13.5) 
Birthweight [Mean (SD)] 2091.0 (588.1) 3043.1 (459.3) 
Gestational age at delivery [Mean (SD)] 33.6 (3.0) 39.0 (1.2) 
Diagnosed with congenital anomaly 21 (14.4) 56 (9.8) 
aPrepregnancy BMI based on n=356. 
bPrepregnancy BMI defined as underweight (<18.5 kg/m2), normal weight (18.5 to <25 kg/m2), 
overweight (25 to <30 kg/m2), obese (≥30 kg/m2). 
SD=standard deviation, GED=general educational development, BMI=body mass index 
 
(Table 6 continued)  
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Table 7. Rate of neonatal abstinence syndrome by opioid maintenance treatment and 
preterm birth status. 
Treatment Term with NAS Term without 
NAS 
Preterm with 
NAS 
Preterm without 
NAS 
Total 
Methadone 223 81 40 63 407 
Buprenorphine 140 126 12 31 309 
Total 363 207 52 94 716 
NAS=neonatal abstinence syndrome 
64 
Table 8. Opioid maintenance therapy-NAS association and opioid maintenance therapy-NAS association not attributable to 
preterm birth in women exposed to opioid maintenance therapy at Magee-Womens Hospital, 2013 to 2015 using inverse 
probability weighted marginal structural models (n=716). 
 
  Risk Differencesa: 
RD per 100 live born infants (95% CI) 
Risk Ratiosb:  
RR (95% CI) 
Proportion 
Explained on RD 
Scale 
 Events 
(n) 
Population 
at risk 
(n) 
Unadjusted risk 
per 100 live 
born infants 
Total 
association: 
OMT-NAS  
Association not 
attributed to preterm 
birth: 
Total 
association: 
OMT-NAS  
Association not 
attributed to 
preterm birth: 
Proportion of total 
avoided by 
preterm birth 
Methadone 
Buprenorphine 
263 
152 
407 
309 
64.6 
49.2 
13.3 (5.7, 20.9) 
Reference 
16.7 (9.3, 24.0) 
Reference 
1.26 (1.10, 1.45) 
Reference 
1.34 (1.17, 1.53) 
Reference 
24.9% 
 
 
a Linear risk models adjusted for parity, maternal race, age, employment status, smoking status, marital status, hepatitis C status, 
private vs. public insurance, and year of delivery. 
b Poisson regression models adjusted for parity, maternal race, age, employment status, smoking status, marital status, hepatitis C 
status, private vs. public insurance, and year of delivery. 
 
OMT=opioid maintenance therapy, NAS=neonatal abstinence syndrome, RD=risk difference, RR=risk ratio, CI=confidence interval 
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5.1 ABSTRACT 
Objective To predict risk of recurrent spontaneous preterm birth based on obstetric history, 
accounting for interplay between variables, in women treated with 17-OHPC.  
Design Secondary analysis of a randomized controlled trial (Omega-3 Trial; 2005-2006). 
Setting 13 Maternal-Fetal Medicine Units across the U.S. 
Population Women with prior spontaneous preterm delivery (sptd) at 200 to 366 receiving 
weekly injections of 17-OHPC (n=754). 
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Methods Backwards, chunk-wise, model building methods were used to create log binomial 
regression models predictive of recurrent preterm birth. Models included interaction terms 
between obstetric history variables and were externally validated for discrimination and 
calibration. 
Main Outcome Measures Spontaneous delivery prior to 37 weeks’ gestation. 
Results Approximately 35% (n=267) of the pregnancies ended in a recurrent sptd. The predictive 
model had moderate discrimination with good calibration. Predicted risk of recurrence was 
higher in women with more prior preterm deliveries, fewer term deliveries, and earlier 
gestational ages at delivery of the most recent pregnancy. Risk also increased with earliest 
gestational ages of prior delivery, however this effect was only seen in women with two or more 
previous spontaneous preterm deliveries. An average women with 1 previous sptd and no prior 
term deliveries had a risk ranging from 27.0 (95% CI: 18.4, 35.6) to 31.5 (95% CI: 24.7, 38.3) 
regardless of the age of her earliest delivery. However, predicted risk increased significantly with 
earlier gestational ages of prior delivery in women with two or more previous sptds [(risk for 
average woman with 2 prior sptds and earliest at 20 weeks: 47.4 (29.1, 65.7); risk for average 
woman with 2 prior sptds and earliest at 36 weeks: 19.4 (7.7, 31.2)].  
Conclusions Factors in obstetric history have an important impact on one another. Risk of 
recurrent preterm delivery is similar for women with only one prior sptd, regardless of 
gestational at which it occurred. More work is needed to target treatment with 17-OHPC beyond 
identification of women with a single previous sptd.  
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5.2 INTRODUCTION 
Nearly 1 of every 10 live born infants is delivered preterm (<37 weeks) in the United States [50]. 
Preterm birth continues to be one of the leading the causes of infant morbidity and mortality 
contributing to an estimated 75% of all perinatal deaths, despite progress in preventive treatment 
[5, 6, 48]. 
It has been well established that the greater number of prior spontaneous preterm births a 
woman has, the more likely she is to have a recurrent preterm birth [53-56]. The American 
College of Obstetricians and Gynecologists (ACOG) recommends administration of 17- alpha 
hydroxyprogesterone caproate (17-OHPC) injections for women with a prior spontaneous 
preterm delivery to reduce the risk of recurrence [7, 8, 98]. However, response rates are highly 
variable with about 30-40% ‘failing’ treatment and delivering preterm [8].  
Targeting this pharmacologic intervention to women most likely to respond has been a 
recent priority in the field of obstetrics [99, 100], but has been complicated by the fact that both 
the pathophysiology of preterm birth and mechanism of action 17-OHPC remain unknown. A 
few known obstetric history factors that influence the risk of recurrence include gestational age 
at earliest preterm delivery [59, 62], number and pattern of previous preterm and term deliveries 
[54], gestational age of the  most recent previous pregnancy [53, 56, 63], and clinical 
presentation of previous spontaneous preterm delivery [56, 61]. However, extant literature does 
not consistently agree on which factors are most important in predicting risk despite treatment 
nor do they adequately address the interplay between various pregnancy history characteristics. 
It would be valuable to both provider and patient to estimate a woman’s risk of recurrent 
preterm delivery while receiving 17-OHPC. Differentiating between inherent risks of various 
obstetric history patterns will 1) identify which patients are at a highest risk of recurrence, and 2) 
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lead to the question: “Is it appropriate to administer identical pharmacotherapy with 17-OHPC to 
all women with one previous spontaneous preterm delivery?” 
We sought to address these questions by creating an externally validated predictive 
model, inclusive of interactions between pregnancy histories, using the National Institute of 
Child Health and Human Development Maternal-Fetal Medicine Units (NICHD MFMU) 
Omega-3 Trial [101]. This model will help to granulate risk profiles and tailor the predicted risk 
of recurrent spontaneous preterm birth to the woman’s obstetric history pattern, ultimately 
targeting treatment to those most likely to respond. 
5.3 METHODS 
Population 
We performed a secondary analysis of the NICHD MFM ‘Omega-3 Trial’. This was a double-
blind, randomized, placebo-controlled trial of omega-3 fatty acid supplementation to prevent 
preterm birth in addition to 17-OHPC administration in high risk pregnancies. The original trial 
has been described in detail previously [101]. Briefly, a total of 852 pregnant women with at 
least one previous preterm delivery (between 200 and 366 weeks gestation) were administered 
weekly injections of 250mg 17-OHPC from randomization until 366 weeks or delivery, 
whichever occurred first. In addition to this treatment, women were randomized to receive a 
daily supplement of omega-3 long-chain polyunsaturated fatty acids or placebo. Authors found 
no significant effect of omega-3 supplementation on recurrent preterm birth [101]. 
In the randomized controlled trial (RCT), data pertinent to inclusion and exclusion were 
reviewed directly in the patient’s chart. All demographic and history variables (medical, 
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obstetric, social) were obtained in patient interview at randomization followed by a review of the 
patient’s chart. This retrospective, secondary analysis was exempt from our Institutional Review 
Board’s approval 
 
Predictors 
We defined primary exposure as gestational age of the earliest spontaneous preterm birth (20-27, 
28-33, 34-36 weeks per RCT data). The following pregnancy history characteristics were 
identified a priori as potential modifiers of the effect of the primary exposure based on the 
literature: number of previous spontaneous preterm deliveries (1, 2, or ≥3), gestational age of 
most recent pregnancy (<20, 20-36, ≥37 weeks), and the percent of previous births delivered 
preterm. After evaluation for effect modification, those obstetric history variables not classified 
as interactions were included in the final model as exposures of interest.  
Potential baseline factors confounding the association between gestational age of earliest 
previous spontaneous preterm delivery and recurrent spontaneous preterm delivery were grouped 
into three categories: 1) maternal demographics (maternal race, age, marital status, years of 
schooling), 2) clinical conditions (prepregnancy BMI, diabetes, chlamydia or gonorrhea), and 3) 
behavioral history (smoking status, consumption of alcoholic drinks, street drug use, marijuana 
use). 
Obstetric history variables of interest included total number of pregnancies, total number 
of term deliveries (none, 1, ≥2), history of previous spontaneous loss prior to 20 weeks, history 
of previous elective termination, classification of most recent previous pregnancy [delivery ≥37 
weeks, spontaneous preterm labor with delivery, preterm premature rupture of membranes 
(pPROM) leading to spontaneous preterm delivery, preterm delivery for fetal or maternal 
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indications, spontaneous loss <20 weeks, preterm intrapartum stillbirth], and the gestational age 
of most recent pregnancy.  
 
Outcomes 
We defined our primary outcome as spontaneous preterm delivery prior to 37 weeks’ gestation as 
this dictates administration of 17-OHPC in subsequent pregnancies in the US [7]. Gestational age 
was estimated using a combination of last menstrual period and the earliest dating ultrasound. 
Secondary outcomes included more clinically relevant preterm birth defined as delivery prior to 
35 weeks and prior to 32 weeks. These were referred to as ‘late-’ and ‘early-’ preterm birth, 
respectively, in this paper.  
5.3.1 Analysis 
Associated risks were assessed using log binomial regression models, or Poisson distribution 
when the model would not converge, to estimate risk ratios with associated 95% confidence 
intervals. We assessed interaction between the gestational age of earliest spontaneous preterm 
birth (primary exposure) and the potential effect modifiers on both additive and multiplicative 
scales. The synergy index was used to assess additive interaction, and a change in the risk ratio 
of >10% after addition of the interaction term indicated significant interaction on the 
multiplicative scale. Wald tests were evaluated to confirm significance of each interaction term.  
 
Model building 
Model building was completed by hand using a chunk-wise, backwards variable selection 
process. Covariates were added by grouping described above: 1) maternal demographics, 2) 
clinical conditions, then 3) behavioral history. All variables with a p-value greater than 0.2 were 
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removed from the model. Variables remaining significant in the model from each group were 
then combined with the significant interaction terms to create the optimal, parsimonious 
predictive model. All obstetric history variables were included in the final model to facilitate risk 
predictions for various history patterns.  
 
Model validation and performance assessment 
The predictive model was externally validated using data from treated women in the landmark 
randomized controlled trial conducted by Meis et al. through the NICHD MFMU Network 
(details in Appendix C).[8]  
We assessed the calibration of the model graphically by comparing the predicted preterm 
delivery rates to the observed in both the original study and in the Meis trial. Discrimination of 
the model was assessed using receiver operating characteristic (ROC) curves and corresponding 
c-statistics. We used the final model to predict the risk of recurrent spontaneous preterm delivery 
in hypothetical women with various obstetric history patterns using the margins command.  
Model building and prediction of risk was then repeated with late- and early- preterm birth as the 
outcome (delivery prior to 35 and 32 weeks’ gestation). All analyses were conducted in Stata 
14.0 (StataCorp, Texas). 
5.4 RESULTS 
Further limiting the original Omega-3 cohort (n=854), we excluded women with a compliance of 
less than 50% with the 17-OHPC injection (n=41), a cervical length of less than 2.5 cm (n=13), 
those missing a gestational age at delivery (n=1), all indicated preterm deliveries (n=42), and 1 
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woman with no documented previous spontaneous preterm deliveries. Our final analytic sample 
included 754 women (Appendix C: Figure 5). 
Slightly over one-third (35%) of the pregnancies treated with 17-OHPC ended in a 
spontaneous preterm delivery (n=267 at <37 weeks; n=128 at <35 weeks; n=67 at <32 weeks). 
Women with a recurrent preterm delivery were more likely to be non-Hispanic White, have less 
education, and to smoke at baseline (Table 9). Women with term deliveries had less previous 
spontaneous preterm deliveries, occurring at later gestational ages, more previous term 
deliveries, with their last pregnancy more likely to have ended in a term delivery (Table 9). 
Maternal age, pre-pregnancy body mass index (BMI), marital status, parity, number of elected 
terminations and spontaneous losses, and route of delivery of current pregnancy were similar 
between groups.  
The only significant interaction on an additive and multiplicative scale was between 
gestational age of earliest spontaneous preterm delivery and number of previous spontaneous 
preterm deliveries. This interaction term demonstrated a significant Wald test (p<0.0001), a 
synergy index of 5.8 (-19.0, 30.6), and a contour graph displaying curvature indicative of 
interaction with 2 or more previous spontaneous preterm deliveries (Appendix C: Figure 6).  
 
Recurrent Spontaneous Preterm Delivery 
Backwards, step-wise model building resulted in a final regression modeling the risk of recurrent 
spontaneous preterm delivery by the variables described in Figure 7 (Appendix C). The final 
model of recurrent spontaneous preterm delivery prior to 37 weeks was well calibrated, 
demonstrating similar predicted and observed outcomes even in the lowest and highest deciles of 
predicted risk (Figure 2). The final model exhibited moderate discrimination in the Omega-3 data 
with a c-statistic of 0.71 (95% CI: 0.67, 0.74). In the external validation the calibration was 
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slightly decreased, but discrimination was not significantly different from the original data with a 
c-statistic of 0.70 (95% CI: 0.64, 0.77) (Figure 2). 
 
Recurrent Late- and Early- Spontaneous Preterm Delivery 
Backwards, step-wise model building modeling for late- and early- recurrent spontaneous 
preterm delivery resulted in similar final models (Appendix C: Figures 8 and 9). When externally 
validated in the Meis trial, which had a total of 57 late- and 33 early- spontaneous preterm 
deliveries, the model demonstrated reasonable calibration and increased ROCs compared to the 
primary analysis (Appendix C: Figures 8 and 9). The c-statistic was increased in both the original 
and external data. 
 
Predicting Risk 
Using the final model, predicted risk of recurrent spontaneous preterm delivery before 37 weeks 
is shown, 1) for significant predictors of recurrence independently (Figure 3), and 2) with the 
interplay of these variables in women with no previous term deliveries (Figure 4).  
Women with earlier previous spontaneous preterm deliveries (≤33 weeks) incurred 
significant additional risk of recurrence compared with 34-36 weeks only in women with two or 
more previous spontaneous preterm deliveries (Figure 3, Panel A). Risk of recurrence was 
inversely related to the number of previous term deliveries (Figure 3, Panel B) and gestational 
age of most recent delivery (Figure 3, Panel C). Women with no previous term deliveries 
(n=491) and those delivering before 20 weeks in their most recent pregnancy (n=99) had the 
highest predicted risk. The associations with number of term births and earliest gestational age 
were consistent irrespective of number of previous spontaneous preterm deliveries. 
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Figure 4 demonstrates again that predicted risk of recurrence decreased when the earliest 
previous spontaneous preterm delivery occurred later (34-36 weeks), but only in women with 
two or more previous spontaneous preterm deliveries. The risk of recurrent preterm delivery was 
similar for women with only one previous spontaneous preterm and no previous term deliveries 
ranging from 27.0 (95% CI: 18.4, 35.6) to 31.5 (95% CI: 24.7, 38.4), regardless of earliest 
gestational age (Figure 4). The protective effect of previous term deliveries slightly decreased all 
risks similarly (Appendix C: Figure 10). 
Three women in the study met the criteria for highest hypothetical risk based on obstetric 
history: ≥3 prior spontaneous preterm deliveries, earliest occurring at 20-27 weeks, the most 
recent pregnancy delivered before 20 weeks with no history of a term birth. The predicted risk of 
recurrent spontaneous preterm delivery in these women was 100% which correlated exactly with 
the observed rate (n=3) in this cohort, despite treatment. A woman with the same high risk 
history but the earliest previous spontaneous preterm delivery occurring between 34 to 36 weeks 
had a predicted risk of recurrence of 57%. No women in this cohort had this pattern of obstetric 
history. 
Conversely, women were expected to be at the lowest risk of recurrence if they had only 
1 previous spontaneous preterm delivery, the most recent pregnancy was a term delivery, and 2 
or more previous term deliveries (n=12). Regardless of the gestational of the earliest spontaneous 
preterm delivery, women with this pattern had a predicted risk of recurrence 15 to 18% and an 
observed rate from 0 to 25%.  
Predictions of recurrence prior to 35- and 32- weeks followed similar patterns with 
consistently lower risk predictions. Confidence intervals of risk estimates were wider for these 
less frequent outcomes. 
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5.5 DISCUSSION 
Main findings 
We have developed models to predict the risk of recurrent preterm term birth (prior to 37-, 35-, 
and 32- weeks) while receiving 17-OHPC, based primarily on a woman’s obstetric history 
highlighting the interplay between these factors. With good discrimination and calibration, these 
models were used to estimate risk of recurrence when receiving standard treatment and dosing of 
17-OHPC. Our results demonstrate that women with only one previous spontaneous preterm 
delivery have similar risk of recurrence regardless of the age of their earliest pregnancy. The 
increased risk associated with earliest gestational age has the most impact after two or more 
previous spontaneous preterm deliveries. Conversely, the protective effect seen with increased 
number of prior term deliveries and the increased risk with earlier gestational age of most recent 
pregnancy are consistent irrespective of number of previous spontaneous preterm deliveries.  
 
Strengths and limitations 
As with all observational studies, our findings must be viewed within the bounds of its 
limitations. The primary restrictions in this paper result directly from our study cohort. First, 
without a placebo group we were unable to evaluate absolute risk reductions and therefore could 
not assess efficacy of 17-OHPC. This is important as women with a predicted risk of 30% and 
70% may have the same risk reduction and benefit from 17-OHPC, depending on their inherent 
initial risk. Second, and perhaps most importantly, there is sparse data in certain history patterns 
resulting in wide confidence intervals of risk predictions. For instance, only 45 women in the 
cohort have had 3 or more previous spontaneous preterm births, and only 5 of those had an 
earliest gestational age in the range of 34 to 36 weeks. Though we categorized variables to 
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maintain sufficient samples in each pattern, this limited our ability to create a robust clinical tool 
for risk prediction. Additionally, beta coefficients which have been used in the past to compare 
risk impact, were not interpretable in our model due to the interaction term.  
In addition, the original RCT did not collect documentation of preventative treatment in 
previous pregnancies. This is unlikely to impact our findings as the majority of women in this 
trial only had one previous spontaneous preterm delivery, making the study pregnancy the first 
eligible for treatment. Additionally, the landmark Meis trial was not published until 2003 leaving 
little time for 17-OHPC to be adopted as standard practice before this trial. 
Despite these limitations, our study also had a few notable strengths. Notwithstanding the 
vast amount of literature assessing the role of obstetric history in recurrent preterm birth, no 
study to date has assessed the interplay between these characteristics. It is reasonable to expect 
that the risk associated with one factor, for example number of previous spontaneous preterm 
births, would be modified by another such as the age at which the earliest occurred. Assessing 
each of these individually rather than in concert is a gap in the literature that we filled by 
including significant interactions in our predictive model along with generating predictions for 
individual patterns rather than interpreting individual beta coefficients. 
Our modeling approaches utilizing binomial regression instead of a logistic model, which 
is commonly used, were less likely to overestimate the risk. Furthermore, our modeling allowed 
focus on obstetric history while including significant demographic, clinical, and behavioral 
characteristics that are readily available in the woman’s chart. All obstetric variables were 
included in the model to facilitate predictions for a large array of history patterns-regardless of 
statistical significance. We were also not limited by documentation of compliance with the 
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burdensome weekly regimen as this was collected in the RCT and we limited the sample to 
women with >50% compliance. 
 
Interpretation 
Our overall findings of associations between recurrence and number of previous spontaneous 
preterm deliveries, gestational age of earliest and most recent pregnancy, and number of term 
deliveries is generally consistent with extant literature. Nonetheless, contrary to our results, in a 
secondary analysis of the landmark Meis trial [8], authors found that the risk associated with 
number of previous spontaneous preterm births was only present in the placebo group and not 
those treated with 17-OHPC [53]. Their results suggest that treatment may be most beneficial in 
women with phenotypes shared for recurrent preterm births. Opposite these findings, in our 
study cohort of treated women the association between number of prior spontaneous preterm 
deliveries and recurrent preterm delivery remained significant. Moreover, we found that women 
with high recurrence numbers and early ages were in fact most likely to have a subsequent 
preterm delivery despite treatment.   
Another study of interest, utilizing the Omega-3 trial data but with major differences in 
objective, was conducted by Manuck et al [63]. These authors aimed to develop a clinical 
scoring method to predict non-response to treatment with 17-OHPC. In an attempt to better 
classify utility of 17-OHPC, they defined response as prolongation of gestation by 3 or more 
weeks past a patient’s earliest preterm birth. The final analytic sample in this study consisted of 
595 ‘responders’ (of which 27% still had a preterm birth) and 159 ‘nonresponders’. Using 
multivariate logistic regression they identified two obstetric history variables associated with 
‘nonresponse’: each additional week of gestation of earliest previous preterm birth (OR 1.23, 
95% CI: 1.17, 1.30) and a penultimate preterm birth (OR 2.10, 95% CI: 1.03, 4.25). No further 
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obstetric history variables were tested in the multivariable analysis. When this prediction model 
was externally validated it had a sensitivity and specificity of 65% and 67%, respectively. 
Distinct from our results, authors concluded that additional weeks of gestation in the earliest 
pregnancy increased the woman’s likely to not respond. This opposite conclusion is likely due to 
the disregard of the interplay between characteristics and simply interpreting odds ratios of 
independent risk factors, or it may be a result of their unique outcome definition. Despite these 
limitations, an added value of this work is the exploration of genetic risks significant in 
predicting nonresponse [62].  
The similar risk for women with one previous spontaneous preterm delivery regardless of 
the gestational age at which it occurs is a novel finding. We are confident in these findings as 
sample size is largest for women with only one previous spontaneous preterm delivery and the 
predicted and observed risks both support this conclusion. As a clinical example, consider 
Patient A as an average woman with only one prior pregnancy ending in a spontaneous preterm 
delivery at 20 weeks. Her predicted risk of recurrence is 29.2 (95% CI: 20.6, 37.7). In that same 
woman, if the previous delivery instead occurred at 36 weeks her risk would slightly decrease to 
25.8 (19.2, 32.4).  However, if instead she had 2 prior spontaneous preterm deliveries, then when 
the earliest delivery occurred at 20 weeks the predicted risk increases to 47.4 (29.1, 65.7) 
compared with a risk of 19.4 (7.7, 31.2) when the earliest delivery occurred at 36 weeks. These 
findings suggest that women with only one prior spontaneous preterm delivery are too diverse a 
group, comprised of multiple phenotypes of preterm birth, which results in a similar average risk 
profile. Conversely, women with a history of recurrence may share phenotypes that are 
potentially resistant to treatment, particularly for phenotypes associated with early preterm 
delivery.  
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We are less confident in results indicative of “100% predicted risk” as few women 
comprise these high risk profiles, resulting in unstable estimates with wide confidence intervals. 
Nevertheless, in women who remain at a 100% predicted and observed risk of recurrence there 
are two possible explanations for treatment failure. The first explanation, as preterm delivery is 
an outcome with numerous causes, it is possible that 17-OHPC does not target certain 
phenotypes through its mechanism of action. 17-OHPC may act on a pathway that is different 
and more amenable to treatment than to that which is shared with recurrent, early preterm 
deliveries. The second possibility is an insufficient dose based on demographic or phenotypic 
characteristics.  
 
Conclusions 
Our findings contribute to the argument that utilization of a blanket treatment protocol of 17-
OHPC for all women with a history of only one previous spontaneous preterm birth is inefficient. 
With more research in larger populations to confirm and expand these findings, we hope to better 
target treatment by individual risk and phenotype beyond a single previous spontaneous preterm 
birth. This paper adds clarity and begins to stratify risk by obstetric history, facilitating a patient-
specific profile which will direct treatment to those most likely to benefit.  
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5.6 TABLES AND FIGURES 
Table 9. Baseline demographics of women in study cohort by recurrent spontaneous 
delivery prior to 37 weeks’ gestation (n=754). 
Characteristic Spontaneous Preterm Delivery 
N (%) 
n=267 
Term Delivery  
N (%) 
n=487 
Race 
    NH White 
    NH Black 
    Hispanic 
   Other 
 
151 (56.5) 
92 (34.5) 
19 (7.1) 
5 (1.9) 
 
230 (47.2) 
152 (31.2) 
89 (18.3) 
16 (3.3) 
Maternal age [Mean (SD)] 27.1 (5.4) 28.0 (5.5) 
Years of maternal schooling 
    ≤6 years  
    7-12 years 
     ≥13 years 
 
2 (0.8) 
131(49.0) 
134 (50.2) 
 
6 (1.2) 
201 (41.3) 
280 (57.5) 
Pre-pregnancy BMI [Mean (SD)] 26.3 (6.9) 26.6 (6.6) 
Married 192 (71.9) 337 (69.2) 
Smoker 50 (18.3) 65 (13.4) 
Parity  
    1 previous pregnancy 
    2 previous pregnancies 
    3 or more pregnancies 
 
126 (47.2) 
75 (28.1) 
66 (24.7) 
 
228 (46.8) 
153 (31.4) 
106 (21.8) 
Diabetes  3 (1.1) 8 (1.6) 
Street drug use  5 (1.9) 9 (1.9) 
Number of previous SPTDs 
    1  
    2  
    ≥3  
 
176 (65.9) 
59 (22.1) 
32 (12.0) 
 
386 (79.1) 
88 (18.0) 
13 (2.7) 
Gestational age of earliest sptd 
    20-27 weeks 
    28-33 weeks 
    34-26 weeks 
 
83 (31.1) 
109 (40.8) 
75 (28.1) 
 
130 (26.6) 
167 (34.2) 
190 (38.9) 
Gestational age of most recent pregnancy 
    <20 weeks 
    20- 27 weeks 
    28-33 weeks 
    34-36 weeks 
 
38 (14.2) 
48 (18.0) 
86 (32.2) 
76 (28.5) 
 
61 (12.5) 
88 (18.1) 
111 (22.8) 
162 (33.3) 
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    ≥37 weeks 
 
19 (7.1) 
 
65 (13.3) 
Number of previous term deliveries 
    0  
    1  
    ≥2  
 
192 (71.9) 
50 (18.7) 
25 (9.4) 
 
299 (61.4) 
119 (24.4) 
69 (14.2) 
History of elected termination(s)  36 (13.5) 74 (15.2) 
History of spontaneous loss(es) at <20 weeks 86 (32.2) 153 (31.4) 
Delivery classification of most recent pregnancy 
    Delivery ≥37 weeks  
    Spontaneous PTL with delivery  
    PROM leading to spontaneous PTD  
    PTD for fetal indications  
    PTD for maternal indications  
    Spontaneous loss <20 weeks  
    Preterm intrapartum stillbirth 
 
19 (7.1) 
137 (51.3) 
66 (24.7) 
0 (0) 
2 (0.8) 
38 (14.2) 
5 (1.9) 
 
65 (13.4) 
211 (43.3) 
131 (26.9) 
5 (1.0) 
4 (0.8) 
61 (12.5) 
10 (2.1) 
aNH=non-Hispanic, SD=standard deviation, SPTD=spontaneous preterm delivery; SD=standard 
deviation; ptd=preterm delivery; PTL=preterm labor; PROM=premature rupture of membranes 
(Table 9 continued) 
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Figure 2. Discrimination and calibration of the predictive model for recurrent spontaneous 
preterm delivery prior to 37 weeks. 
*ROC= receiver operating characteristic curve; AUC= area under the curve; SPTD= spontaneous 
preterm delivery 
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Figure 3. Risk of recurrent sptd before 37 weeks gestation by number of prior sptds, 
earliest gestational age (Panel A), number of previous term deliveries (Panel B), and 
gestational age of the most recent pregnancy (Panel C) with all other variables at means. 
SPTD=spontaneous preterm delivery, GA=gestational age 
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Figure 4. Risk of recurrent sptd before 37 weeks by number of prior sptds and earliest 
gestational age in women with no previous term deliveries with all other variables at their 
mean. 
SPTD=spontaneous preterm delivery, GA=gestational age 
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6.0  SYNTHESIS 
6.1 OVERVIEW OF FINDINGS 
The global purpose of this dissertation was to apply pharmacoepidemiologic methods to 
relevant clinical issues encountered by obstetric care providers when prescribing 
medication in pregnancy. We did so by addressing optimization of two medication therapies 
used in pregnancy, 1) opioid maintenance therapy, and 2) 17-OHPC for secondary prevention of 
preterm birth. Using a retrospective cohort of 716 women treated with opioid maintenance 
therapy at Magee-Womens Hospital, Pittsburgh we addressed aims 1 and 2. To assess aim 3 we 
utilized data from 754 women enrolled in the National Institute of Child Health and Human 
Development (NICHD) Maternal Fetal Medicine Units (MFMU) Network Omega-3 trial.  The 
findings of this work are summarized below. 
Specific Aim 1. To estimate the association between in utero exposure to methadone compared 
with buprenorphine and neonatal abstinence syndrome after accounting for unmeasured 
confounding by severity of maternal addiction.  
 Using an internal validation cohort with intensive chart review, we informed a 
probabilistic bias analysis accounting for maternal addiction severity. Methadone and 
buprenorphine exposure were determined using pharmacy billing codes with confirmation in 
chart review. Neonatal abstinence syndrome (NAS) was defined as neonatal treatment with 
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morphine according to pharmacy billing. We found, contrary to our hypothesis, that the historical 
decreased risk of NAS associated with buprenorphine was not fully explained by unmeasured 
confounding attributable to maternal addiction severity.  
Specific Aim 2. To describe and quantify the role of preterm birth in the association between 
opioid maintenance therapy and neonatal abstinence syndrome. 
 Implementing a marginal structural model with inverse probability weighting to account 
for confounding, we assessed the impact of preterm birth as a mediator of the relationship 
between opioid maintenance therapy and NAS. Our hypothesis was based on the following 
associations: 1) methadone is associated with preterm birth, and 2) preterm birth is associated 
with decreased risk of NAS. Results confirmed our hypothesis that the increased risk of NAS 
after methadone exposure in utero compared with buprenorphine was stronger among a 
population of term compared with preterm births. 
Specific Aim 3. To build a predictive model that elucidates the interrelationship between 
pregnancy histories on the risk of recurrent spontaneous preterm birth among women treated 
prophylactically with weekly 17-alpha-hydroxyprogesterone caproate injections. 
 Using backwards, chunk-wise, model building approaches after assessing interactions 
between obstetric history variables, we built a predictive model for recurrent spontaneous 
preterm delivery (at <37 weeks, <35 weeks, and <32 weeks) despite treatment with 17-OHPC. 
Using this model we predicted risks for various obstetric historical patterns. Our analysis 
demonstrated that women with only 1 previous spontaneous preterm delivery had similar 
predicted risk regardless of the gestational age at which it occurred and the amount of previous 
term deliveries. Put differently, risk attributable to earliest gestational age in a previous 
pregnancy was only seen in women with 2 or more previous spontaneous preterm deliveries. 
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Other confirmed associations did not vary by the amount of previous spontaneous preterm 
deliveries. 
6.2 STRENGTHS AND LIMITATIONS 
As with all research, our conclusions must be considered in light of their limitations, but also has 
notable strengths.  
6.2.1 Opioid maintenance therapies 
Misclassification 
Opioid maintenance therapy documented on the day of delivery or up to one week prior to 
delivery was used for classification of exposure. This method was used as the majority of women 
do not receive their opioid maintenance medication directly from the hospital and we lacked 
information on retail claims. It is therefore possible that exposure for the entire pregnancy period 
was misclassified, particularly if therapy was changed from buprenorphine to methadone as the 
reverse is clinically contraindicated. Misclassification would result in an underestimate of the 
observed association for Chapters 3 and 4 (Manuscripts 1 and 2). However, in our validation 
subcohort, only 6 of 200 women had documentation of switching therapies, including changing 
therapies from a previous pregnancy or prior to knowing they were pregnant. It is therefore 
unlikely that many women were exposed to both treatments in one pregnancy and consequently 
is not expected to significantly impact the results.  
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Defining NAS as neonatal treatment with morphine limits assessment to the most severe 
cases of NAS. We chose to focus on the treated infants for three reasons. First, the Finnegan 
Scale has been criticized for being too subjective, thus potentially resulting in additional 
misclassification of outcome. Second, treated infants typically have the longer stays and are 
therefore associated with the highest costs. Third, we did not have access to Finnegan scores nor 
the morphine dosing required to treat withdrawal. Therefore, though having a gradient of 
Finnegan scores or morphine dose may be preferable, those receiving treatment incur the largest 
costs and this approach is subject to less misclassification due to the subjectivity of the Finnegan 
Scale. 
 
Unmeasured confounding 
Though the aim of Chapter 3 was to estimate the effect without unmeasured confounding, some 
likely remains in both Chapters 3 and 4. Accounting for all potential confounders is particularly 
difficult because the pathophysiology of NAS is unknown. Therefore, identifying factors that are 
associated with NAS and treatment, and further differentiating confounders from mediators is 
challenging. Under the rules of causal inference in the mediation analysis, residual unmeasured 
confounding violates the assumption of exchangeability. This is a limitation we share with most, 
if not all, observational studies.  
 
Parameterizing maternal addiction 
We are the first to use an internal validation cohort to derive information on severity to adjust for 
unmeasured confounding; however, our findings are subject to the bounds of the data available 
to us and to the parameterization the severity index. Our severity index was restricted by the 
variables recorded in the chart and was further limited by differential missingness by treatment. 
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Because of sample size, we relied on any marker of severity as indicative as “severe addiction”. 
This approach was shown to be robust regardless of which variable was used to create the index. 
Ideally, a future prospective study will evaluate severity of each woman’s addiction using a 
validated scale such as the Addiction Severity Index  [102].  Despite these limitations, our 
approach is preferable to deriving effect estimates exclusively from the literature.  
 
Missing data: Lacking detailed treatment and addiction trajectories 
The social judgement incurred by this population was a primary contributor to the amount of 
missing data in the validation cohort (Chapter 3). The stigma associated with opioid use 
dependence is a finding consistent across studies of similar populations, one that is exacerbated 
in pregnancy. 
The amount of missing data and the differences by treatment in the validation cohort was 
a primary limitation of this analysis. To assess the impact of missing data in Chapter 3 we 
performed the analysis with ‘bound’ estimates in the validation cohort. When we performed our 
analysis as a “worst case” scenario where all missing in the methadone group was assumed to be 
“yes” and all missing in the buprenorphine group was coded as “no”, 97% of the methadone 
group was classified as having severe addiction compared with 32% in the buprenorphine group. 
Using the Flanders and Khoury method with this new severity index under the “worst case” 
scenario assumptions, the lowest association was increased to 1.38 (compared with 1.13 using 
the original index). Performing the probabilistic bias analysis informed using this bias parameter 
provided results similar to those using the literature values. Conclusions were the same 
demonstrating that confounding by maternal addiction did not fully explain the association 
between methadone and NAS. For Chapter 4 there was very minimal missing data in the total 
cohort and therefore had little impact on the results. 
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Because we lacked detailed information on treatment and addiction trajectories in our 
cross sectional data, we were unable to define the temporality of certain relationships. Therefore, 
the adjustment represented only one hypothetical relationship among the variables. For example, 
it is reasonable to assume that lack of insurance could increase a woman’s addiction severity if 
she cannot afford treatment. Conversely, it is also reasonable to assume that a woman with 
severe addiction may be less likely to be employed and therefore have no insurance. Not 
knowing the temporality of these associations prohibited the development of a true direct acyclic 
graph to dictate adjustments. Moreover, without information on the initiation, timing, and 
duration of exposure to medication, we were unable to appropriately assess how these factors 
influence the development of NAS. 
In Chapter 4, the lack of temporality and information on treatment trajectories and 
gestational age at initiation could have introduced immortal time bias if women receiving opioid 
maintenance therapy were not converted to treatment until after 37 weeks [42]. However, the 
validation cohort from Chapter 3 found that no women were initiated on treatment after 36 
weeks eliminating this concern. 
 
Causal assumption violations 
Interpreting the mediation analysis (Chapter 4), must be done within the confines of four primary 
assumptions: positivity, no interference, exchangeability, and counterfactual consistency [96]. Of 
these, only exchangeability (described above) and counterfactual consistency are potentially 
violated in our study.  
Counterfactual consistency requires that both the relationship between treatment-preterm 
birth and preterm birth-NAS are causal. A large amount of extant data support the relationship 
between methadone and preterm birth [17, 37, 39, 43, 44], providing us with confidence in this 
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association. However, the relationship between preterm birth-NAS presented a larger challenge 
as the pathophysiology of both are unknown. We were therefore forced to make the assumption 
that this relationship is causal based on the commonly accepted biologic plausibility that the 
association results from immature opioid-receptor development in the neonate [23]. 
6.2.2 17-OHPC 
Study cohort 
Using data collected prospectively from a randomized controlled trial is a strength of this study 
as there is very little missing data. Moreover, demographics were obtained from patient 
interview then confirmed in the medical record, decreasing the likelihood of misclassification. 
Nevertheless, the primary limitation in Chapter 5 results directly from the sample size and design 
of this cohort.  
The majority of the women in the cohort (75%) had only 1 previous spontaneous preterm 
delivery. Therefore very few women had obstetric history patterns with at least 3 previous 
preterm births and this varied by gestational age of the earliest preterm delivery. For example, of 
the 45 women with 3 or more previous spontaneous preterm deliveries, only 5 had an earliest 
gestational age of 34 to 36 weeks. This was expected as women with more previous preterm 
deliveries typically have poorer history profiles and are associated with earlier gestational ages 
(i.e. <34 weeks). However, the sparseness of data in specific historical patterns resulted in 
unstable estimates with wide confidence intervals. This prohibited the development of a clinical 
tool for recurrence prediction.  
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No placebo group 
Our study was limited to women with a previous spontaneous preterm delivery who were treated 
with 17-OHPC. This approach is clinically relevant as this is standard care recommended by 
ACOG [7]. However, without a placebo group we were unable to assess the efficacy of 17-
OHPC. In order to evaluate the true effect of the drug we would need to assess absolute, rather 
than relative, risk reductions. For instance, a women with a poor history profile (e.g. earliest 
gestational age of 20 weeks, 3 previous preterm deliveries, and no previous terms) may have a 
much higher inherent risk than a women with only 1 previous preterm delivery at 36 weeks. Both 
could have a risk reduction of 20% due to use of 17-OHPC and the risk of the first patient still 
remain at 70% compared to only 10% for the woman with a more favorable history. 
Unfortunately we could not address this factor with the data available to us. 
6.3 PUBLIC HEALTH AND CLINICAL IMPLICATIONS 
Contributing to a field that suffers from a dearth of data to guide clinical decisions is 
indisputably important. We applied pharmacoepidemiologic methods to contribute to two 
frequently encountered and high public health priorities in pregnancy: opioid use dependence 
and recurrent preterm birth.  
Opioid use, both prescription and heroin, has reached epidemic proportions in the U.S. 
[12]. This marked increase in abuse and dependence has impacted women of reproductive age 
including those who are pregnant [103]. Because opioid maintenance therapy is recommended 
over drug detoxification in pregnancy [4], determining which treatment provides optimal 
outcomes for both mother and fetus is of the utmost importance. Withdrawal in the infant after in 
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utero exposure, termed neonatal abstinence syndrome (NAS), is one of the most costly and 
detrimental outcomes associated with treatment [85]. This dissertation adds to the argument for 
treatment availability of both approved opioid maintenance therapies as buprenorphine is 
associated with less NAS compared with methadone. Decreasing the incidence of NAS suffered 
by these infants improves long term outcomes for these children, reduces maternal fear due to 
neonatal exposure, and reduces healthcare costs by avoiding longer NICU stays and treatment. 
This work advocates for expansion of buprenorphine use in pregnancy through extended access 
and increased number of licensed buprenorphine providers.  
Another obstetric challenge that has yet to be overcome despite treatment is preterm 
birth. In the U.S. preterm birth occurs at a rate of about 10% and contributes to 75% of all 
perinatal deaths [5]. The public health significance of this occurrence cannot be overstated. 
Though treatment with 17-OHPC has been widely adopted for prevention of recurrence in 
women with a previous spontaneous preterm delivery, targeting this treatment to women most 
likely to respond has not been successful. The predictive models created in this dissertation 
began to stratify the risk of treatment failure by obstetric history. In women with 100% predicted 
recurrence, new therapies targeting different mechanisms of action need to be explored.  
This work may alter treatment preferences for women with an opioid use disorder in 
pregnancy and begins to facilitate a patient-specific risk profile targeting treatment with 17-
OHPC in various formulations to those most likely to benefit. Overall this work demonstrated 
the utility of applying epidemiologic methods to the study of medication use in pregnancy. 
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6.4 FUTURE RESEARCH  
Future studies should apply our approach to minimize unmeasured confounding by severity of 
maternal addiction to other outcomes associated with opioid maintenance therapy that are of 
public health significance such as fetal growth, length of stay in the NICU, NAS severity and 
others. Impact of maternal addiction severity may vary for each outcome, all of which contribute 
to clinical decision making and determining optimal treatment. Performing such studies in a 
population with documented addiction and medication histories would be valuable to evaluate 
cumulative effects of exposure. These results can be strengthened in a cohort utilizing a validated 
tool assessing maternal addiction severity. Subsequent health policy and economic studies 
evaluating the effect of expanded access to treatment options are also warranted. 
Basic science studies evaluating how each opioid maintenance therapy effects the 
placenta are also needed. It is biologically plausible that the increased risk of preterm birth 
associated with methadone results from morphologic changes in the placenta [104]. Furthermore, 
neonatal exposure to the opioid agonists may vary by structure of each medication. Defining 
these mechanisms and elucidating the pathophysiology of NAS will guide methods to decrease 
neonatal risk. 
Furthermore, dosing for both mother and neonate should be studied at a basic science 
level. Current maternal dosing, both initiation and maintenance, are based on subjective 
measures and tools such as the Clinical Opioid Withdrawal (COW) score. A critical contribution 
to the field would be development of a new tool to objectively evaluate withdrawal and dose to 
appropriate blood concentration levels to avoid this. This same approach would be extremely 
beneficial in administration of morphine to infants. The ability to determine doses and length of 
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treatment on objective measures, such as blood concentration, rather than Finnegan Scores could 
help to avoid excess exposure of the infant and periods of withdrawal.  
The predictive models for recurrent preterm birth need to be replicated in a population 
with more women in the highest risk strata, while still assessing for interaction between the 
variables. Ideally, models will be built in both a treated and non-treated group with similar 
histories, though this is not likely feasible as women with later previous preterm deliveries more 
frequently refuse prophylactic treatment. A novel approach to address this inherent bias with an 
observational cohort of treated and untreated women (both with documented previous 
spontaneous preterm delivery), would be to implement a propensity score to assess the true 
efficacy of the medication in a matched sample.  
To provide the most clinically applicable results, similar studies should be repeated 
assessing prolongation of gestation rather than binary preterm-term birth. Predicting gestational 
age rather than risk of recurrence, provides the healthcare provider valuable information to 
evaluate benefit. For instance, in a women with an earliest previous gestational age of 21 weeks, 
prolongation of gestation in her next pregnancy to 34 weeks is clinically beneficial, though still 
classified as a recurrent preterm delivery.  
Finally, a critical area of importance for future work is to define both the mechanism of 
action of 17-OHPC and the pathophysiology of preterm birth. Pharmacologic and physiologic 
studies elucidating the various phenotypes will allow for more tailored preventative therapies to 
be developed and applied. These studies also have the potential to identify necessary dose 
alterations after establishing a dose-concentration-response relationship. For example, women 
with higher body mass indices may require a larger dose of 17-OHPC to reach effect due to a 
larger distribution of the drug and subsequent lower concentration.  
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Though the opportunity and need for future research on these topics is vast— this 
dissertation work provides a significant contribution. Our research on both opioid maintenance 
therapies and 17-OHPC can be utilized by clinical organizations such as ACOG to help inform 
future treatment practice recommendations.  
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APPENDIX A: MANUSCRIPT 1 – SUPPLEMENTAL CONTENT 
Opioid maintenance therapy selection protocol at Magee-Womens Hospital 
At Magee-Womens Hospital, initiation of opioid maintenance therapy with methadone or 
buprenorphine is determined by the patient, provided the patient is not already on a stable opioid 
maintenance regimen and does not concurrently use benzodiazepines (self-reported or on urine 
drug screen). Women who are using benzodiazepines, a sedative drug, are allocated to 
methadone treatment as they will require inpatient tapering from both opioids and 
benzodiazepines. Methadone-treated patients are converted to methadone during an inpatient 
admission where the dose is titrated to the mother’s Clinical Opioid Withdrawal (COW) Score. 
After discharge they are provided the medication daily at one of several outpatient opioid 
treatment clinics.  
After the establishment of the Pregnancy Recovery Center at Magee-Womens Hospital in 
July of 2014, eligible women treated with buprenorphine were able to receive their medication at 
a hospital-based outpatient clinic. The treatment protocol for buprenorphine is also based on the 
COW score. Once a stable dose is achieved, women are provided up to a 2 week supply of 
medication allowing them to dose themselves daily at home without a need for hospitalization or 
a daily clinic visit. Prior to the Pregnancy Recovery Center, women were referred to outside 
buprenorphine clinics with DEA approved providers for treatment. Outside clinics remain a 
utilized option at this institution. Women who are discontinued from the Pregnancy Recovery 
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Center due to signs of ongoing illicit substance abuse will be converted to methadone at Magee-
Womens Hospital or transferred to an outside buprenorphine provider. Methadone treated 
women will not be converted to buprenorphine in pregnancy.  
Selecting bias analysis parameters 
The first severity indicator determined by the research team, time of conversion, was 
determined based on clinical experience and consistent with previous literature that women with 
more controlled addiction were more likely to conceive while receiving opioid maintenance 
therapy. Women with uncontrolled addiction were determined to be more likely to avoid seeking 
treatment until later in pregnancy. These women with more uncontrolled addiction were also 
more likely to relapse and to continue to use illicit substances despite treatment. These factors 
were considered indicative of a more severe addiction with higher degrees of maladaptive 
compulsive drug-seeking behavior.  
Benzodiazepines are sedative prescription drugs that can accentuate the “high” associated 
with opioid abuse while also increasing risk of overdose when used concomitantly with opioids. 
It has been found that persons abusing both substances have more social dysfunction which can 
potentially be used clinically as a marker of a more severe addiction. 
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Table 10. Demographics of women in study cohort vs. all deliveries Magee-Women 
Hospital in Pittsburgh from 2013 through 2014. 
   
Characteristic Study cohort 
N (%)  
n=716 
All deliveries at MWH 
N (%)  
n= 20,565 
Race 
    White 
    Black 
    Other 
    Missing 
 
675 (94.3) 
27 (3.8) 
1 (0.1) 
13 (1.8) 
 
14,835 (72.1) 
4, 085 (19.9) 
771 (3.8) 
874 (4.2) 
Mother’s age [Mean (SD)] 28.8 (4.8) 29.1 (5.6) 
Mother’s Education 
    Less than high school 
    High school graduate or GED completed 
    Some college credit 
    College graduate 
    Missing 
 
128 (17.8) 
304 (42.5) 
146 (20.4) 
120 (16.8) 
18 (2.5) 
 
1,129 (5.5) 
3,329 (16.2) 
2,087 (10.2) 
9,591 (46.6) 
4,429 (21.5) 
Prepregnancy BMI [Mean (SD)]a,b 24.4 (5.7) 26.4 (6.6) 
Marriedc 93 (13.0) 11,938 (58.1) 
Smoked during pregnancy 586 (81.8) 1,891 (9.2) 
Parityd  
    Nulliparous 
    1-2 previous pregnancies 
    Greater than 2 pregnancies 
 
224 (31.3) 
359 (50.1) 
133 (18.6) 
 
9,473 (46.1) 
9,493 (46.2) 
1,586 (7.7) 
Gestational age at delivery [Mean (SD)]e 37.9 (2.8) 38.5 (2.6) 
Birthweight [Mean (SD)]f 2849 (621) 3269 (620) 
Infant with congenital anomaly 77 (10.8) 2 (0.01) 
aPrepregnancy BMI in full cohort based on n=356. 
bPrepregnancy BMI in all deliveries based on n=14,753. 
cMarried in all deliveries based on n=20,432. 
dParity in all deliveries based on n=20,552. 
eGestational age in all deliveries based on n=20,302 
fBirthweight in all deliveries based on n=20,073     
MWH=Magee-Womens Hospital, GED=general education development, SD=standard deviation, 
BMI=body mass index 
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Table 11. Demographics of women in validation cohort vs. total study cohort at Magee-
Womens Hospital in Pittsburgh from 2013 through 2015. 
Characteristic Validation cohort 
N (%) 
n=200 
Full cohort 
N (%) 
n=716 
Race 
   White 
    Black 
    Filipino 
    Missing 
 
194 (97.0) 
5 (2.5) 
0 (0) 
1  (0.5) 
 
675 (94.3) 
27 (3.8) 
1 (0.1) 
13 (1.8) 
Mother’s age [Mean (SD)] 28.4 (5.1) 28.8 (4.8) 
Mother’s Education 
    Less than high school 
    High school graduate or GED completed 
    Some college credit 
    College graduate 
    Missing 
 
28 (14.1) 
92 (46.2) 
41 (20.6) 
33 (16.6) 
6 (2.5) 
 
128 (17.8) 
304 (42.5) 
146 (20.4) 
120 (16.8) 
18 (2.5) 
Prepregnancy BMI [Mean (SD)]a,b 24.1 (5.5) 24.4 (5.7) 
Married 29 (14.6) 93 (13.0) 
Employed 74 (37.2) 274 (38.3) 
Smoked during pregnancy 163 (82.7) 586 (81.8) 
Parity  
    Nulliparous 
    1-2 previous pregnancies 
    Greater than 2 pregnancies 
 
70 (35.2) 
94 (46.7) 
36 (18.1) 
 
224 (31.3) 
359 (50.1) 
133 (18.6) 
Hepatitis c positive 22 (11.1) 92 (12.9) 
Gestational age at delivery [Mean (SD)] 38.2 (2.7) 37.9 (2.8) 
Birthweight [Mean (SD)] 2920 (601) 2849 (621) 
Infant with congenital anomaly 25 (12.6) 77 (10.8) 
aPrepregnancy BMI in validation cohort based on n=97. 
bPrepregnancy BMI in full cohort based on n=356. 
GED=general education development, SD=standard deviation, BMI=body mass index 
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Table 12. Demographics of women diagnosed with drug-dependent deliveries of singletons 
by treatment for neonatal abstinence treatment from 2013 through 2015 (n=716). 
Characteristic Treated for NAS 
N (%) 
n=415 
Not Treatment for NAS 
N (%) 
n=301 
Race 
   White 
    Black 
    Missing 
 
389 (93.7) 
17 (4.1) 
9 (2.2) 
 
286 (95.0) 
10 (3.3) 
5 (1.7) 
Mother’s age [Mean (SD)] 28.8 (4.8) 28.8 (4.8) 
Mother’s Education 
    Less than high school 
    High school graduate or GED completed 
    Some college credit 
    College graduate 
    Missing 
 
80 (19.3) 
179 (43.1) 
79 (19.0) 
67 (16.2) 
10 (2.4) 
 
48 (15.9) 
125 (41.5) 
67 (22.3) 
53 (17.6) 
8 (2.7) 
Prepregnancy BMI [Mean (SD)] a 24.6 (5.3) 24.2 (6.1) 
BMI categoryb 
    Underweight (<18.5kg/m2) 
    Normal weight 
    Overweight 
    Obese 
    Missing 
 
17 (4.1) 
130 (31.3) 
35 (8.5) 
25 (6.0) 
208 (50.1) 
 
11 (3.6) 
80 (26.7) 
30 (9.9) 
28 (9.3) 
152 (50.5) 
Married 49 (11.8) 44 (14.6) 
Employed 150 (36.1) 124 (41.2) 
Smoked during pregnancy 336 (81.0) 250 (83.1) 
Parity  
    Nulliparous 
    1-2 previous pregnancies 
    Greater than 2 pregnancies 
 
129 (31.1) 
212 (51.1) 
74 (17.8) 
 
95 (31.6) 
147 (48.8) 
59 (19.6) 
Hepatitis c positive 62 (14.9) 30 (10.0) 
Gestational age at delivery [Mean (SD)] 38.5 (1.8) 37.1 (3.6) 
Birthweight [Mean (SD)] 2953 (506.6) 2704 (727.6) 
Infant with congenital anomaly 35 (8.4) 42 (14.0) 
aPrepregnancy BMI based on n=356. 
bPrepregnancy BMI defined as underweight (<18.5 kg/m2), normal weight (18.5 to <25 kg/m2), 
overweight (25 to <30 kg/m2), obese (≥30 kg/m2). 
NAS=neonatal abstinence syndrome, GED=general education development, SD=standard 
deviation, BMI=body mass index  
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Table 13. Amount of missing data on severity indices abstracted from medical charts per 
woman by opioid maintenance type in a subsample of opioid use dependent women at 
Magee-Women Hospital in Pittsburgh, 2013-2015 (n=200). 
Number of Variables 
Missing 
Methadone 
N=100 
Buprenorphine 
N=100 
None 16 11 
1 variable 32 17 
2 variables 25 28 
3 variables 17 35 
All 4 variables 10 9 
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Description of Flanders and Khoury method. Data informing these associations was obtained 
directly from logistic regressions in the validation subcohort. 
• OREC =7.11 
• ORDC =1.21 
• 1/PC+E- =3.13 
• ORDC/ (QC+E- +ORDC* PC+E-) =1.13 
• OREC / (QC+E- +OREC *PC+E-) =2.41 
Per the Flanders and Khoury method, the minimum of these values is the upper limit of 
RR due to confounding. Therefore, 1.13 becomes the maximum value of RR due to confounding 
thereby becoming the upper limit of the trapezoidal distribution. 
*OR=odds ratio, EC=exposure-confounder, DC=disease-confounder, P=prevalence, Q=1-
prevalence, RR=relative risk 
 
 
Worst case scenario approach of addressing missing data is defined as all missing data coded 
as “yes” in the methadone group and “no” in the buprenorphine group. 
 
Sensitivity of bias analysis (worst case scenario of missing data severity index): 
• OREC = 68.71 (20.22, 233.51) 
• ORDC = 1.68 (0.94, 3.02) 
• 1/PC+E- = 3.13 
• ORDC/ (QC+E- +ORDC* PC+E-) =1.38 
• OREC / (QC+E- +OREC *PC+E-) =3.03 
• The upper limit of the RR due to confounding is increased to 1.38 
*OR=odds ratio, EC=exposure-confounder, DC=disease-confounder, P=prevalence, Q=1-
prevalence, RR=relative risk  
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Table 14. Comparison of results from adjusted conventional and probabilistic bias analyses 
accounting for unmeasured confounding by severity of addiction on the risk of NAS 
associated with methadone compared with buprenorphine, at MWH, Pittsburgh, 
Pennsylvania. 
Opioid 
maintenance 
therapy 
Conventional analysis: 
Adjusteda relative risk 
(95% confidence 
interval) 
Bias Analysis 1:  
Adjusteda point 
estimate  
(95% bootstrapped 
simulation interval)b 
Bias Analysis 2:  
Adjusteda point 
estimate  
(95% bootstrapped 
simulation interval)c 
Buprenorphine 
Methadone 
Reference 
1.3 (1.1, 1.5) 
Reference 
1.1 (0.9, 1.3) 
Reference 
1.1 (0.9, 1.3) 
aAdjusted for parity, maternal race, employment status, hepatitis c status, age, year of delivery, 
smoking status, marital status, and private vs. public insurance. 
bminimum RRC=1.0, mode 1=1.08, mode 2=1.3, maximum RRC=1.38 
cminimum RRC=1.0, mode 1=1.1, mode 2=1.28, maximum RRC=1.38 
RRc=relative risk due to confounding 
These results demonstrate findings using a “worst case” scenario approach in which all missing 
data is coded as “yes” in the methadone group and “no” in the buprenorphine group. 
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APPENDIX B: MANUSCRIPT 2 – MEDIATION SUPPLEMENTARY TABLE 
Table 15. Opioid maintenance therapy-NAS association and opioid maintenance therapy-NAS association not attributable to 
preterm birth in women exposed to opioid maintenance therapy at Magee-Womens Hospital, 2013 to 2015 using the 
generalized product method (n=716).a 
  Risk Differencesb: 
RD per 100 live born infants  
(95% CI) 
Risk Ratiosc:  
RR (95% CI) 
Proportion 
Explained on 
RD Scale 
 Events 
(n) 
Population 
at risk 
(n) 
Unadjusted risk 
per 100 live 
born infants 
Total association: 
OMT-NAS  
Association not 
attributed to 
preterm birth: 
Total association: 
OMT-NAS  
Association not 
attributed to 
preterm birth: 
Proportion of 
total avoided 
by preterm 
birth 
Methadone 
Buprenorphine 
263 
152 
407 
309 
64.6 
49.2 
13.3 (5.4, 20.6) 
Reference 
16.6 (9.2, 23.5) 
Reference 
1.23 (0.17, 8.73) 
Reference 
1.25 (0.17, 8.85) 
Reference 
24.8% 
 
a All results using the generalized product method are bootstrapped. 
b Linear risk models adjusted for parity, maternal race, age, employment status, smoking status, marital status, hepatitis c status, 
private vs. public insurance, and year of delivery. 
c Poisson regression models adjusted for parity, maternal race, age, employment status, smoking status, marital status, hepatitis c 
status, private vs. public insurance, and year of delivery. 
 
OMT=opioid maintenance therapy, NAS=neonatal abstinence syndrome, RD= risk difference, RR= risk ratio, CI= confidence interval 
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APPENDIX C: MANUSCRIPT 3 – 17 OHPC SUPPLEMENTAL CONTENT 
Description of Meis Trial 
The landmark trial assessing the utility of 17-OHPC was conducted by Meis et al. in 
2003. This was a double-blind, placebo-controlled RCT conducted at 19 clinical centers from 
1998-1999. Recruitment was limited to women with at least one previous spontaneous preterm 
delivery between 20 and 366 weeks of gestation. Participants were randomized in a 2:1 manner to 
treatment with weekly 250mg injections of 17-OHPC (n=310) or inert oil placebo (n=153) 
beginning at 16 to 206 weeks gestation and continuing through 366 weeks gestation or until 
delivery. These authors found that 17-OHPC significantly decreased the risk of recurrent preterm 
birth prior to 37 weeks (RR 0.66, 95% CI: 0.54, 0.81) and at less than 32 weeks (RR 0.58, 95% 
CI: 0.37, 0.91).  
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Table 16. Demographics of women in Omega-3 cohort compared with Meis trial at 
baseline. 
Characteristic Omega-3 
N (%) 
n=754 
Meis et al.  
N (%) 
n=310 
Race 
    NH White 
    NH Black 
    Hispanic 
   Other 
 
381 (50.5) 
244 (32.4) 
108 (14.3) 
21 (2.8) 
 
79 (25.5)  
183 (59.0) 
43 (13.9) 
5 (1.6) 
Mother’s age [Mean (SD)] 27.7 (5.5) 26 (5.6) 
Years of maternal schooling 
    ≤6 years  
    7-12 years 
     ≥13 years 
 
8 (1.2) 
332 (44.0) 
414 (54.9) 
 
11 (3.6) 
216 (69.7) 
83 (26.8) 
Prepregnancy BMI [Mean (SD)] 26.5 (6.7) 26.7 (7.4) 
BMI categorya 
    Underweight  
    Normal weight 
    Overweight 
    Grade 1 obesity 
    Grade 2 obesity 
    Grade 3 obesity    
    Missing 
 
39 (5.2) 
326 (43.2) 
177 (23.5) 
113 (15.0) 
51 (6.8) 
40 (5.3) 
8 (1.1) 
 
26 (8.4) 
115 (36.8) 
65 (21.0) 
46 (14.8) 
22 (7.1) 
25 (8.1) 
12 (3.9) 
Married 529 (70.2)  159 (51.3) 
Smoked 115 (25.3) 70 (22.6) 
Chlamydia or gonorrhea 24 (3.2) 14 (4.5) 
Marijuana use 12 (1.6) 9 (2.9) 
Alcohol use 59 (7.8) 27 (8.7) 
Parity  
    1 previous pregnancy 
    2 previous pregnancies 
    3 or more pregnancies 
 
354 (47.0) 
228 (30.2) 
172 (22.8) 
 
105 (33.9) 
105 (33.9) 
100 (32.2) 
Diabetes  11 (1.5) 13 (4.2) 
Street drug use prior to randomization 14 (1.9) 11 (3.6) 
aPrepregnancy BMI defined as underweight (<18.5 kg/m2), normal weight (18.5 to <25 kg/m2), 
overweight (25 to <30 kg/m2), grade 1 obesity (30 to <35 kg/m2), grade 2 obesity (35to <40 
kg/m2), grade 3 obesity (≥40 kg/m2). 
NH=non-Hispanic, SD=standard deviation, BMI=body mass index 
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Table 17. Pregnancy histories in Omega-3 trial compared with Meis et al. trial. 
Characteristic Omega-3 
N (%) 
n=754 
Meis et al.  
N (%) 
n=310 
Number of previous sptds 
    1 previous sptds 
    2 previous sptds 
    3 or more previous sptds 
 
562 (74.5) 
147 (19.5) 
45 (6.0) 
 
235 (75.8) 
51 (16.5) 
24 (7.7) 
Gestational age of earliest sptd [Mean(SD)] 30.3 (4.6) 29.8 (4.9) 
Class of gestational age of earliest sptd 
    20 to 27 weeks 
    28 to 33 weeks 
    34 to 36 weeks 
 
213 (28.3) 
276 (36.6) 
265 (35.1) 
 
98 (31.6) 
106 (34.2) 
106 (34.2) 
Gestational age of penultimate pregnancy 29.5 (8.0) 32.1 (5.5) 
Class of gestational age of penultimate pregnancy 
    <20 weeks 
    20 to 27 weeks 
    28 to 33 weeks 
    34 to 36 weeks 
    37+ weeks 
 
99 (13.1) 
136 (18.0) 
197 (26.1) 
238 (31.6) 
84 (11.1) 
 
---- 
70 (22.6) 
84 (27.1) 
87 (28.1) 
69 (22.3) 
Number of previous term deliveries 
    0 previous term  
    1 previous term 
    2 or more previous terms 
 
491 (65.1) 
169 (22.4) 
94 (12.5) 
 
157 (50.7) 
93 (30.0) 
60 (19.3) 
Number of previous PTDs 
    1 previous ptds 
    2 previous ptds 
    3 or more previous ptds 
 
540 (71.6) 
166 (22.0) 
48 (6.4) 
 
224 (72.2) 
56 (18.1) 
30 (9.7) 
Number of previous elected terminations 
    0 previous terminations 
    1 previous termination 
    2 or more previous terminations 
 
644 (85.4) 
66 (8.8) 
44 (5.8) 
 
259 (84.4) 
38 (12.4) 
10 (3.2) 
Number of previous spontaneous loss at <20 weeks 
    0 losses 
    1 loss 
    2 or more losses 
 
515 (68.3) 
164 (21.8) 
75 (9.9) 
 
217 (73.8) 
59 (20.1) 
18 (6.1) 
Gestational age of qualifying pregnancy [Mean(SD)] 31.0 (4.5) 30.6 (4.6) 
Route of delivery 
    Vaginal 
    Cesarean section 
 
577 (76.5) 
177 (23.5) 
 
229 (74.8) 
77 (25.2) 
SPTD=spontaneous preterm delivery, SD=standard deviation, PTD=preterm delivery 
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Figure 5. Flow diagram describing sample population included in secondary analysis 
(n=754, 2005-2006). 
sptd= spontaneous preterm delivery 
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Figure 6. Interaction between gestational age of earliest spontaneous preterm delivery and 
number of previous spontaneous preterm deliveries. 
SPTD= spontaneous preterm delivery 
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Figure 7. Model building: outcome= spontaneous preterm delivery <37 weeks; primary exposure: gestational age of earliest 
previous spontaneous preterm birth. Using generalized linear models with Poisson distribution. 
aClassification of most recent pregnancy:  Delivery ≥37 weeks, spontaneous PTL with delivery, PROM leading to spontaneous PTD, PTD for fetal 
indications, PTD for maternal indications, spontaneous loss <20 weeks, preterm intrapartum stillbirth 
bsptd=spontaneous preterm delivery, BMI=body mass index, GA=gestational age, PTL=preterm labor, PROM=premature rupture of membranes 
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Figure 8. Discrimination and calibration of the predictive model for recurrent mid-sptd 
prior to 35 weeks. 
*ROC= receiver operating characteristic curve; AUC= area under the curve; SPTD= spontaneous 
preterm delivery 
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Figure 9. Discrimination and calibration of the predictive model for recurrent early- sptd 
prior to 32 weeks. 
*ROC= receiver operating characteristic curve; AUC= area under the curve; SPTD= spontaneous
preterm delivery
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Figure 10. Risk of recurrent sptd before 37 weeks gestation by number of prior sptds, 
earliest gestational age and number of previous term deliveries taken together with all other 
variables at their mean. 
SPTD=spontaneous preterm delivery, GA=gestational age 
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